

Serial No.: 10/812,075

Author Search

=> FILE.CAPLUS

FILE 'CAPLUS' ENTERED AT 10:39:22 ON 05 JUN 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 5 Jun 2007 VOL 146 ISS 24

FILE LAST UPDATED: 4 Jun 2007 (20070604/ED)


Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>



'OBI' IS DEFAULT SEARCH FIELD FOR 'CAPLUS' FILE

=> D QUE L25

L8 STR



Structure attributes must be viewed using STN Express query preparation:
Uploading strB.str



chain nodes :
 7 8 9 10 11 12 13 16
 ring nodes :
 1 2 3 4 5 6
 chain bonds :
 2-7 6-8 8-9 9-10 10-11 11-12 11-13
 ring bonds :
 1-2 1-6 2-3 3-4 4-5 5-6
 exact/norm bonds :
 2-7 6-8 8-9 9-10 10-11 11-12
 exact bonds :
 11-13
 normalized bonds :
 1-2 1-6 2-3 3-4 4-5 5-6

Connectivity :
 16:1 E exact RC ring/chain
 Match level :
 1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:Atom 10:CLASS
 11:CLASS 12:CLASS 13:Atom 16:CLASS 17:Atom
 Generic attributes :
 13:
 Saturation : Unsaturated
 Type of Ring System : Monocyclic
 Element Count :
 Node 9: Limited
 C,C5-8
 Node 13: Limited
 C,C6

| | | | | | | |
|-----|------|-----|---------------|--------|--------|-----------------|
| L13 | 278 | SEA | FILE=REGISTRY | SSS | FUL | L8 |
| L14 | 3 | SEA | FILE=CAPLUS | ABB=ON | PLU=ON | L13 |
| L15 | 902 | SEA | FILE=CAPLUS | ABB=ON | PLU=ON | SEKIGUCHI Y?/AU |
| L16 | 32 | SEA | FILE=CAPLUS | ABB=ON | PLU=ON | KANUMA K?/AU |
| L17 | 21 | SEA | FILE=CAPLUS | ABB=ON | PLU=ON | OMODERA K?/AU |
| L18 | 19 | SEA | FILE=CAPLUS | ABB=ON | PLU=ON | BUSUJIMA T?/AU |
| L19 | 2458 | SEA | FILE=CAPLUS | ABB=ON | PLU=ON | TRAN T?/AU |




Serial No.: 10/812,075

L20 9406 SEA FILE=CAPLUS ABB=ON PLU=ON HAN S?/AU
 L21 54 SEA FILE=CAPLUS ABB=ON PLU=ON CASPER M?/AU
 L22 757 SEA FILE=CAPLUS ABB=ON PLU=ON KRAMER B?/AU
 L23 92 SEA FILE=CAPLUS ABB=ON PLU=ON SEMPLE G?/AU
 L24 95 SEA FILE=CAPLUS ABB=ON PLU=ON ZOU N?/AU
 L25 3 SEA FILE=CAPLUS ABB=ON PLU=ON (L15 OR L16 OR L17 OR L18 OR
 L19 OR L20 OR L21 OR L22 OR L23 OR L24) AND L14

=> D IBIB ED ABS HITSTR 1-3 L25

L25 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2006:464826 CAPLUS Full-text
 DOCUMENT NUMBER: 144:488666
 TITLE: Preparation of quinoline, tetrahydroquinazoline, and
 pyrimidine derivatives as MCH antagonist for treatment
 of CNS disorders
 INVENTOR(S): Sekiguchi, Yoshinori; Kanuma, Yukihiro;
 Omodera, Katsunori; Busujima, Takeshi
 ; Tran, Thuy-Ahn; Han, Sangdong;
 Casper, Martin; Brian, A. Kramer; Semple,
 Graeme; Zou, Ning
 PATENT ASSIGNEE(S): Taisho Pharmaceutical Co., Ltd., Japan; Arena
 Pharmaceutical Inc.
 SOURCE: Jpn. Kokai Tokkyo Koho, 781 pp.
 CODEN: JKXXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|-----------------------------|------|----------|-------------------|------------|
| JP 2006124387 | A | 20060518 | JP 2005-286311 | 20050930 |
| PRIORITY APPLN. INFO.: | | | JP 2004-287659 | A 20040930 |
| OTHER SOURCE(S): | | | MARPAT 144:488666 | |
| ED Entered STN: 19 May 2006 | | | | |
| GI | | | | |



AB Title compds. [I, II, III; wherein R1 = (un)substituted (cyclo)alkyl, (cyclo)alkenyl, alkynyl, aryl; R2 = H, halo, OH, carboxy, carbamoyl, amino, (un)substituted alkyl, alkoxy; T = independently H, halo, OH, carboxy, carbamoyl, amino, cyano, NO₂, alkenyl, alkynyl, cycloalkyl, (un)substituted alkyl, alkoxy; p = 0-5; L = aminocycloalkylideneamino, etc.; Y = bond, CH₂, CO₂, OCO, SO₂, CO, CS, CONH, CSNH, etc.; with provisos; and pharmaceutically acceptable salts, hydrates, or solvates thereof] were prepared as antagonists of melanin concentrating hormone (MCH), an endogenous ligand of G-protein coupled receptors (GPCRs). Examples include solution and solid phase general synthetic methods and phys. data for nearly 3400 invention compds. In addition, all exemplified compds. were assayed using high throughput functional screening to detect intracellular Ca²⁺ concns. for accessing GPCR activation. For instance, reaction of 2,4-dichloro-6-methylpyrimidine with dimethylamine gave 2-chloro-4-(dimethylamino)-6-methylpyrimidine (40%), which was coupled with cis-(4-aminocyclohexyl)carbamic acid tert-Bu ester (60%). Deprotection (72%), amidation, and workup provided the benzamide (IV)•TFA. The latter demonstrated MCH antagonist activity with an IC₅₀ value of 7.6 nM. Thus, pharmaceutical compns. comprising I are useful for the prophylaxis or treatment of improving memory function, sleeping and arousal, anxiety, depression, mood disorders, seizure, obesity, diabetes, appetite and eating disorders, cardiovascular disease, hypertension, dyslipidemia, myocardial infarction, binge eating disorders including bulimia, anorexia, mental disorders including manic depression, schizophrenia, delirium, dementia, stress, cognitive disorders, attention deficit disorder, substance abuse disorders, and dyskinesias including Parkinson's disease, epilepsy, and addiction (no data).

IT 771545-17-6P 771545-22-3P 773141-41-6P
 773141-63-2P 773141-64-3P 773141-65-4P
 773141-66-5P 773141-67-6P 773141-68-7P
 773141-69-8P 773141-70-1P 773141-72-3P
 773141-79-0P 773142-96-4P 773143-00-3P
 773143-01-4P 773143-05-8P 773143-06-9P
 773143-07-0P 773143-09-2P 773143-10-5P
 773143-16-1P 773143-17-2P 773143-19-4P
 773143-20-7P 773143-21-8P 773143-22-9P
 773143-23-0P 773143-24-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU

Serial No.: 10/812,075


(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(MCH antagonist; preparation of quinolines, quinazolines, and pyrimidines as MCH antagonist for treatment of CNS disorders)

RN 771545-17-6 CAPLUS

CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5,6-dimethyl-2-pyrimidinyl]amino]cyclohexyl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 771545-22-3 CAPLUS

CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5,6-dimethyl-2-pyrimidinyl]amino]cyclohexyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 773141-41-6 CAPLUS

CN Benzamide, 4-chloro-N-[cis-4-[[4-methyl-6-(methylamino)-2-pyrimidinyl]amino]cyclohexyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 773141-63-2 CAPLUS


CN Benzamide, 4-chloro-N-[cis-4-[[4-(dimethylamino)-6-methyl-2-pyrimidinyl]amino]cyclohexyl]-3-fluoro-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 773141-64-3 CAPLUS
 CN Benzamide, 3-chloro-N-[(cis-4-[[4-(dimethylamino)-6-methyl-2-pyrimidinyl]amino]cyclohexyl]-5-fluoro-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 773141-65-4 CAPLUS
 CN Benzamide, N-[(cis-4-[[4-(dimethylamino)-6-methyl-2-pyrimidinyl]amino]cyclohexyl]-3,4,5-trifluoro-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 773141-66-5 CAPLUS

Serial No.: 10/812,075

CN Benzamide, 3-chloro-4-fluoro-N-[cis-4-[[5-methyl-4-(methylamino)-2-pyrimidinyl]amino]cyclohexyl]-, monohydrochloride (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 773141-67-6 CAPLUS

CN Benzamide, 4-chloro-N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-3-fluoro-, monohydrochloride (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 773141-68-7 CAPLUS


CN Benzamide, 3-chloro-N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-5-fluoro-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 773141-69-8 CAPLUS
 CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-3,4,5-trifluoro-, monohydrochloride (9CI)
 (CA INDEX NAME)

Relative stereochemistry.




RN 773141-70-1 CAPLUS
 CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-3,5-difluoro-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 773141-72-3 CAPLUS
 CN Benzamide, N-[cis-4-[(4-amino-5-methyl-2-pyrimidinyl)amino]cyclohexyl]-3-chloro-4-fluoro-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 773141-79-0 CAPLUS
 CN Benzamide, 3-chloro-N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-4-fluoro-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1


CRN 771551-22-5
 CMF C20 H25 Cl F N5 O

Relative stereochemistry.




CM 2

CRN 75-75-2
 CMF C H4 O3 S



RN 773142-96-4 CAPLUS
 CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-3,4-difluoro- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 773143-00-3 CAPLUS

CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-4-(trifluoromethoxy)- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 773143-01-4 CAPLUS

CN Benzamide, 3,4-dichloro-N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 773143-05-8 CAPLUS

CN Benzamide, 3,5-dichloro-N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 773143-06-9 CAPLUS

CN Benzamide, N-[cis-4-[[4-(dimethylamino)-6-methyl-2-pyrimidinyl]amino]cyclohexyl]-3,5-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 773143-07-0 CAPLUS

CN Benzamide, 4-chloro-N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 773143-09-2 CAPLUS

CN Benzamide, 3-chloro-N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-4-(trifluoromethoxy)- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 773143-10-5 CAPLUS

CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-4-[2,2,2-trifluoro-1-hydroxy-1-

Serial No.: 10/812,075

(trifluoromethyl)ethyl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 773143-16-1 CAPLUS

CN Benzamide, 4-chloro-N-[cis-4-[[4-(dimethylamino)-6-methyl-2-pyrimidinyl]amino]cyclohexyl]-3-fluoro- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 773143-17-2 CAPLUS

CN Benzamide, 3-chloro-N-[cis-4-[[4-(dimethylamino)-6-methyl-2-pyrimidinyl]amino]cyclohexyl]-5-fluoro- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 773143-19-4 CAPLUS

CN Benzamide, N-[cis-4-[[4-(dimethylamino)-6-methyl-2-pyrimidinyl]amino]cyclohexyl]-3,4,5-trifluoro- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 773143-20-7 CAPLUS

CN Benzamide, 3-chloro-4-fluoro-N-[cis-4-[[5-methyl-4-(methylamino)-2-pyrimidinyl]amino]cyclohexyl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 773143-21-8 CAPLUS

CN Benzamide, 4-chloro-N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-3-fluoro- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 773143-22-9 CAPLUS

CN Benzamide, 3-chloro-N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-5-fluoro- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 773143-23-0 CAPLUS

CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-3,4,5-trifluoro- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 773143-24-1 CAPLUS

CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-3,5-difluoro- (9CI) (CA INDEX NAME)

Relative stereochemistry.




IT 771544-72-0P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(intermediate; preparation of quinolines, quinazolines, and pyrimidines as melanin-concentrating hormone antagonist for treatment of CNS disorders)

RN 771544-72-0 CAPLUS

CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-3,5-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



IT 771545-85-8P


RL: RCT (Reactant); SPN. (Synthetic preparation); PREP (Preparation); RACT (Reactant, or reagent)

(intermediate; preparation of quinolines, quinazolines, and pyrimidines as melanin-concentrating hormone antagonist for treatment of CNS disorders)

RN 771545-85-8 CAPLUS

CN Benzamide, N- [cis-4-[[4-(ethylmethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-3,4-difluoro- (9CI) (CA INDEX NAME)

Relative stereochemistry.



IT 771543-92-1P 771543-93-2P 771543-95-4P
 771544-42-4P 771544-43-5P 771544-44-6P
 771544-45-7P 771544-46-8P 771544-47-9P
 771544-48-0P 771544-49-1P 771544-50-4P
 771544-68-4P 771544-99-1P 771545-01-8P
 771545-03-0P 771545-04-1P 771545-06-3P
 771545-08-5P 771545-10-9P 771545-12-1P
 771545-18-7P 771545-23-4P 771545-80-3P
 771545-83-6P 771546-31-7P 771546-33-9P
 771546-35-1P 771546-37-3P 771546-39-5P
 771546-41-9P 771546-43-1P 771546-47-5P
 771546-49-7P 771546-51-1P 771546-53-3P
 771546-55-5P 771546-57-7P 771546-59-9P
 771546-61-3P 771546-63-5P 771546-65-7P
 771546-67-9P 771546-69-1P 771546-71-5P
 771546-73-7P 771546-77-1P 771546-79-3P
 771549-06-5P 771549-30-5P 771549-32-7P
 771549-34-9P 771549-36-1P 771549-38-3P
 771549-40-7P 771549-42-9P 771549-44-1P
 771549-46-3P 771549-48-5P 771549-50-9P
 771549-52-1P 771549-54-3P 771549-56-5P
 771549-58-7P 771549-60-1P 771549-62-3P
 771549-64-5P 771549-66-7P 771549-68-9P
 771549-70-3P 771549-78-1P 771549-80-5P
 771549-82-7P 771549-86-1P 771550-50-6P

771550-52-8P 771550-54-0P 771550-56-2P
 771550-58-4P 771550-60-8P 771550-62-0P
 771550-64-2P 771550-66-4P 771550-68-6P
 771550-70-0P 771550-72-2P 771550-74-4P
 771550-76-6P 771550-78-8P 771550-80-2P
 771550-82-4P 771550-84-6P 771550-86-8P
 771550-88-0P 771550-90-4P 771550-92-6P
 771550-94-8P 771550-96-0P 771550-98-2P
 771551-00-9P 771551-02-1P 771551-04-3P
 771551-06-5P 771551-08-7P 771551-12-3P
 771551-14-5P 771551-16-7P 771551-18-9P
 771551-20-3P 771551-22-5P 771551-24-7P
 771551-26-9P 771551-28-1P 771551-30-5P
 771551-32-7P 771551-34-9P 771551-56-5P
 771551-58-7P 771551-60-1P 771551-62-3P
 771551-64-5P 771551-66-7P 771551-68-9P
 771551-70-3P 771551-72-5P 771551-74-7P
 771551-76-9P 771551-78-1P 771551-80-5P
 771551-82-7P 771551-84-9P 771551-86-1P
 771551-88-3P 771551-90-7P 771551-92-9P
 771551-94-1P 771551-96-3P 771551-98-5P
 771552-00-2P 771552-02-4P 771552-04-6P
 771552-06-8P 771552-14-8P 771552-16-0P
 771552-18-2P 771552-20-6P 771552-22-8P
 771552-26-2P 771553-00-5P 771555-36-3P
 771555-45-4P 771556-86-6P 771556-89-9P
 771556-90-2P 771557-07-4P 771557-21-2P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(melanin-concentrating hormone antagonist; preparation of quinolines,
 quinazolines,
 and pyrimidines as melanin-concentrating hormone antagonist for treatment
 of
 CNS disorders)

RN 771543-92-1 CAPLUS

CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5-methyl-2-
 pyrimidinyl]amino]cyclohexyl]-3,4-difluoro-, monohydrochloride (9CI) (CA
 INDEX NAME)

Relative stereochemistry.




● HCl

RN 771543-93-2 CAPLUS

CN Benzamide, 3-chloro-N-[cis-4-[[4-(dimethylamino)-5-methyl-2-
 pyrimidinyl]amino]cyclohexyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771543-95-4 CAPLUS


CN Benzamide, N-[cis-4-[[4-(dimethylamino)-6-methyl-2-pyrimidinyl]amino]cyclohexyl]-3-methyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 771552-18-2

CMF C21 H29 N5 O


Relative stereochemistry.



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 771544-42-4 CAPLUS

CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-3-methyl- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 771544-43-5 CAPLUS

CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-3-methoxy- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 771544-44-6 CAPLUS

CN Benzamide, N-[cis-4-[[4-(dimethylamino)-6-methyl-2-pyrimidinyl]amino]cyclohexyl]-3-methoxy- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 771544-45-7 CAPLUS

CN Benzamide, N-[cis-4-[[4-(dimethylamino)-6-methyl-2-pyrimidinyl]amino]cyclohexyl]-4-methyl- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 771544-46-8 CAPLUS

CN Benzamide, 4-chloro-N-[cis-4-[[4-(dimethylamino)-6-methyl-2-pyrimidinyl]amino]cyclohexyl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 771544-47-9 CAPLUS

CN Benzamide, 3-chloro-N-[cis-4-[[4-(dimethylamino)-6-methyl-2-pyrimidinyl]amino]cyclohexyl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 771544-48-0 CAPLUS

CN Benzamide, N-[cis-4-[[4-(dimethylamino)-6-methyl-2-pyrimidinyl]amino]cyclohexyl]-3,4-difluoro- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 771544-49-1 CAPLUS

CN Benzamide, N-[cis-4-[[4-(dimethylamino)-6-methyl-2-pyrimidinyl]amino]cyclohexyl]-4-(trifluoromethoxy)- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 771544-50-4 CAPLUS

CN Benzamide, N-[cis-4-[[4-(dimethylamino)-6-methyl-2-pyrimidinyl]amino]cyclohexyl]-4-fluoro- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 771544-68-4 CAPLUS

CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-3,5-bis(trifluoromethyl)-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 771544-99-1 CAPLUS


CN Benzamide, 3,5-dibromo-N-[cis-4-[[5-methyl-4-(methylamino)-2-pyrimidinyl]amino]cyclohexyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 771544-98-0

CMF C19 H23 Br2 N5 O


Relative stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 771545-01-8 CAPLUS


CN Benzamide, 3-fluoro-N-[cis-4-[[5-methyl-4-(methylanilino)-2-pyrimidinyl]amino]cyclohexyl]-5-(trifluoromethyl)-, mono(trifluoroacetate)
(9CI) (CA INDEX NAME)

CM 1

CRN 771545-00-7

CMF C20 H23 F4 N5 O


Relative stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 771545-03-0 CAPLUS


CN Benzamide, N-[cis-4-[[5-methyl-4-(methylamino)-2-pyrimidinyl]amino]cyclohexyl]-4-(trifluoromethoxy)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 771545-02-9

CMF C20 H24 F3 N5 O2


Relative stereochemistry.



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 771545-04-1 CAPLUS

CN Benzamide, N-[cis-4-[[5-methyl-4-(methylamino)-2-pyrimidinyl]amino]cyclohexyl]-3,5-bis(trifluoromethyl)-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 771545-06-3 CAPLUS
 CN Benzamide, N-[cis-4-[[4-(ethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-3,4-difluoro-, mono(trifluoroacetate) (9CI)
 (CA INDEX NAME)

CM 1


CRN 771545-05-2
 CMF C20 H25 F2 N5 O

Relative stereochemistry.



CM 2

CRN 76-05-1
 CMF C2 H F3 O2




RN 771545-08-5 CAPLUS
 CN Benzamide, 3,4-difluoro-N-[cis-4-[[5-methyl-4-[(1-methylethyl)amino]-2-pyrimidinyl]amino]cyclohexyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 771545-07-4
CMF C21 H27 F2 N5 O

Relative stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 771545-10-9 CAPLUS
CN Benzamide, N-[cis-4-[[4-(cyclopropylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-3,4-difluoro-, mono(trifluoroacetate) (9CI)
(CA INDEX NAME)

CM 1

CRN 771545-09-6
CMF C21 H25 F2 N5 O


Relative stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 771545-12-1 CAPLUS


CN Benzamide, 3,4-difluoro-N-[cis-4-[[5-methyl-4-(methylamino)-2-pyrimidinyl]amino]cyclohexyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 771545-11-0

CMF C19 H23 F2 N5 O


Relative stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 771545-18-7 CAPLUS

CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5,6-dimethyl-2-pyrimidinyl]amino]cyclohexyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 771545-17-6
CMF C21 H29 N5 O

Relative stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 771545-23-4 CAPLUS
CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5,6-dimethyl-2-pyrimidinyl]amino]cyclohexyl]-3-(trifluoromethyl)-, mono(trifluoroacetate)
(9CI) (CA INDEX NAME)

CM 1


CRN 771545-22-3
CMF C22 H28 F3 N5 O

Relative stereochemistry.




CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 771545-80-3 CAPLUS
 CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5-ethyl-2-pyrimidinyl]amino]cyclohexyl]-3,4-difluoro- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771545-83-6 CAPLUS
 CN Benzamide, N-[cis-4-[[4-(ethylmethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-3,4-difluoro-, monohydrochloride (9CI) (CA INDEX NAME)


Relative stereochemistry.



● HCl

RN 771546-31-7 CAPLUS
 CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-3-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 771546-33-9 CAPLUS

CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-3-(trifluoromethoxy)-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 771546-35-1 CAPLUS

CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-4-(trifluoromethoxy)-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 771546-37-3 CAPLUS

CN Benzamide, 3-chloro-N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-4-(trifluoromethoxy)-, monohydrochloride (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 771546-39-5 CAPLUS

CN Benzamide, 4-chloro-N-[(cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-3-(trifluoromethyl)-], monohydrochloride (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 771546-41-9 CAPLUS

CN Benzamide, 3,5-dichloro-N-[(cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-], monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 771546-43-1 CAPLUS

Serial No.: 10/812,075

CN Benzamide, 3,4-dichloro-N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-, monohydrochloride (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 771546-47-5 CAPLUS

CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-2-(methylsulfonyl)- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 771546-49-7 CAPLUS

CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-3-(methylsulfonyl)- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 771546-51-1 CAPLUS

CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-4-(methylsulfonyl)- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 771546-53-3 CAPLUS

CN Benzoic acid, 2-[[[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]amino]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 771546-55-5 CAPLUS

CN Benzoic acid, 3-[[[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]amino]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 771546-57-7 CAPLUS

CN Benzoic acid, 2-[[[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]amino]carbonyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 771546-59-9 CAPLUS

CN Benzoic acid, 3-[[[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]amino]carbonyl]-, monohydrochloride (9CI)
(CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 771546-61-3 CAPLUS

CN Benzamide, N-[cis-4-[[4-(dimethylamino)-6-methyl-2-pyrimidinyl]amino]cyclohexyl]-3,4-difluoro-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 771546-63-5 CAPLUS

CN Benzamide, N-[cis-4-[[4-(dimethylamino)-6-methyl-2-pyrimidinyl]amino]cyclohexyl]-3,5-bis(trifluoromethyl)-, monohydrochloride (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 771546-65-7 CAPLUS

CN Benzamide, N-[cis-4-[[4-(dimethylamino)-6-methyl-2-pyrimidinyl]amino]cyclohexyl]-4-(trifluoromethoxy)-, monohydrochloride (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 771546-67-9 CAPLUS

CN Benzamide, 3-chloro-N-[cis-4-[[4-(dimethylamino)-6-methyl-2-pyrimidinyl]amino]cyclohexyl]-4-(trifluoromethoxy)-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.




Serial No.: 10/812,075

RN 771546-69-1 CAPLUS

CN Benzamide, 4-chloro-N-[cis-4-[[4-(dimethylamino)-6-methyl-2-pyrimidinyl]amino]cyclohexyl]-, monohydrochloride (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 771546-71-5 CAPLUS

CN Benzamide, 3,4-dichloro-N-[cis-4-[[4-(dimethylamino)-6-methyl-2-pyrimidinyl]amino]cyclohexyl]-, monohydrochloride (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 771546-73-7 CAPLUS

CN Benzamide, N-[cis-4-[[4-(dimethylamino)-6-methyl-2-pyrimidinyl]amino]cyclohexyl]-3,5-dimethoxy- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 771546-77-1 CAPLUS

CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5-methyl-2-

Serial No.: 10/812,075

pyrimidinyl]amino]cyclohexyl]-4-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 771546-79-3 CAPLUS

CN Benzamide, 3-bromo-4-chloro-N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-, monohydrochloride (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 771549-06-5 CAPLUS

CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5,6-dimethyl-2-pyrimidinyl]amino]cyclohexyl]-3-methoxy- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 771549-30-5 CAPLUS

CN Benzamide, 3-cyano-N-[cis-4-[[4-(dimethylamino)-5,6-dimethyl-2-pyrimidinyl]amino]cyclohexyl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 771549-32-7 CAPLUS

CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5,6-dimethyl-2-pyrimidinyl]amino]cyclohexyl]-3-methyl- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 771549-34-9 CAPLUS

CN Benzamide, 3-chloro-N-[cis-4-[[4-(dimethylamino)-5,6-dimethyl-2-pyrimidinyl]amino]cyclohexyl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 771549-36-1 CAPLUS

CN Benzamide, 3-bromo-N-[cis-4-[[4-(dimethylamino)-5,6-dimethyl-2-pyrimidinyl]amino]cyclohexyl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 771549-38-3 CAPLUS

CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5,6-dimethyl-2-pyrimidinyl]amino]cyclohexyl]-3,5-dimethoxy- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 771549-40-7 CAPLUS

CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5,6-dimethyl-2-pyrimidinyl]amino]cyclohexyl]-3,5-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 771549-42-9 CAPLUS

CN Benzamide, 3,4-dichloro-N-[cis-4-[[4-(dimethylamino)-5,6-dimethyl-2-pyrimidinyl]amino]cyclohexyl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 771549-44-1 CAPLUS

CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5,6-dimethyl-2-pyrimidinyl]amino]cyclohexyl]-4-(trifluoromethoxy)- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 771549-46-3 CAPLUS

CN Benzamide, 4-cyano-N-[cis-4-[[4-(dimethylamino)-5,6-dimethyl-2-pyrimidinyl]amino]cyclohexyl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 771549-48-5 CAPLUS

CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5,6-dimethyl-2-pyrimidinyl]amino]cyclohexyl]-4-methyl- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 771549-50-9 CAPLUS

CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5,6-dimethyl-2-pyrimidinyl]amino]cyclohexyl]-4-fluoro- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 771549-52-1 CAPLUS

CN Benzamide, 4-chloro-N-[cis-4-[[4-(dimethylamino)-5,6-dimethyl-2-pyrimidinyl]amino]cyclohexyl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 771549-54-3 CAPLUS

CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5,6-dimethyl-2-pyrimidinyl]amino]cyclohexyl]-2-methoxy- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 771549-56-5 CAPLUS

CN Benzamide, 4-bromo-N-[cis-4-[[4-(dimethylamino)-5,6-dimethyl-2-pyrimidinyl]amino]cyclohexyl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 771549-58-7 CAPLUS

CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5,6-dimethyl-2-pyrimidinyl]amino]cyclohexyl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 771549-60-1 CAPLUS

CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5,6-dimethyl-2-pyrimidinyl]amino]cyclohexyl]-4-ethoxy- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 771549-62-3 CAPLUS

CN Benzamide, 4-bromo-N-[cis-4-[[4-(dimethylamino)-5,6-dimethyl-2-pyrimidinyl]amino]cyclohexyl]-3-methyl- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 771549-64-5 CAPLUS

CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5,6-dimethyl-2-pyrimidinyl]amino]cyclohexyl]-3-fluoro-4-methyl- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 771549-66-7 CAPLUS

CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5,6-dimethyl-2-pyrimidinyl]amino]cyclohexyl]-4-fluoro-3-methyl- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 771549-68-9 CAPLUS

CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5,6-dimethyl-2-pyrimidinyl]amino]cyclohexyl]-3-ethyl- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 771549-70-3 CAPLUS

CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5,6-dimethyl-2-pyrimidinyl]amino]cyclohexyl]-3-(trifluoromethoxy)- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 771549-78-1 CAPLUS

CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5,6-dimethyl-2-pyrimidinyl]amino]cyclohexyl]-3,5-diethoxy- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 771549-80-5 CAPLUS

CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5,6-dimethyl-2-pyrimidinyl]amino]cyclohexyl]-3-ethoxy- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 771549-82-7 CAPLUS

CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5,6-dimethyl-2-pyrimidinyl]amino]cyclohexyl]-3-(1-methylethoxy)- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 771549-86-1 CAPLUS

CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5,6-dimethyl-2-pyrimidinyl]amino]cyclohexyl]-3,4-difluoro- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 771550-50-6 CAPLUS

CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 771550-52-8 CAPLUS

CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-3-fluoro- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 771550-54-0 CAPLUS

CN Benzamide, 3-bromo-N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 771550-56-2 CAPLUS

CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-4-fluoro- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 771550-58-4 CAPLUS

CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-3,5-dimethoxy- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 771550-60-8 CAPLUS

CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-2,4-difluoro- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 771550-62-0 CAPLUS

CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-2,5-difluoro- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 771550-64-2 CAPLUS

CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-2,3,4-trifluoro- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 771550-66-4 CAPLUS

CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 771550-68-6 CAPLUS

CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-4-(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 771550-70-0 CAPLUS

CN Benzamide, 4-butyl-N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 771550-72-2 CAPLUS

CN Benzamide, 4-chloro-N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 771550-74-4 CAPLUS

CN Benzamide, 3-cyano-N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 771550-76-6 CAPLUS

CN Benzamide, 4-cyano-N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.




Serial No.: 10/812,075

RN 771550-78-8 CAPLUS

CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-2-methoxy- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 771550-80-2 CAPLUS

CN Benzamide, 4-bromo-N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 771550-82-4 CAPLUS

CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 771550-84-6 CAPLUS

CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-4-methoxy- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 771550-86-8 CAPLUS

CN Benzamide, 2-bromo-N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 771550-88-0 CAPLUS

CN Benzamide, 2-chloro-N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 771550-90-4 CAPLUS

CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-2-fluoro- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 771550-92-6 CAPLUS

CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-2-methyl- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 771550-94-8 CAPLUS

CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-2-(trifluoromethyl)- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 771550-96-0 CAPLUS

CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-4-fluoro-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 771550-98-2 CAPLUS

CN Benzamide, 4-bromo-N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-3-methyl- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 771551-00-9 CAPLUS

CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-4-ethoxy- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 771551-02-1 CAPLUS

CN Benzamide, 3-(dimethylamino)-N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 771551-04-3 CAPLUS

CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-4-fluoro-3-methyl- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 771551-06-5 CAPLUS

CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-3-fluoro-4-methyl- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 771551-08-7 CAPLUS

CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-3-ethyl- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 771551-12-3 CAPLUS

CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-3-ethoxy- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 771551-14-5 CAPLUS

CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-3-(1-methylethoxy)- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 771551-16-7 CAPLUS

CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-3,5-diethoxy- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 771551-18-9 CAPLUS

CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-3-fluoro-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 771551-20-3 CAPLUS

CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-3-fluoro-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 771551-22-5 CAPLUS

CN Benzamide, 3-chloro-N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-4-fluoro- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 771551-24-7 CAPLUS

CN Benzamide, 3,5-dibromo-N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-4-fluoro- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 771551-26-9 CAPLUS

CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-3,5-dimethyl- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 771551-28-1 CAPLUS

CN Benzamide, 4-chloro-N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-3-methyl- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 771551-30-5 CAPLUS

CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-4-methoxy-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 771551-32-7 CAPLUS

CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-4-methyl- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 771551-34-9 CAPLUS

CN Benzamide, 3-chloro-N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 771551-56-5 CAPLUS

CN Benzamide, N-[cis-4-[[4-(dimethylamino)-6-methyl-2-pyrimidinyl]amino]cyclohexyl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 771551-58-7 CAPLUS

CN Benzamide, 4-butyl-N-[cis-4-[[4-(dimethylamino)-6-methyl-2-pyrimidinyl]amino]cyclohexyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 771551-60-1 CAPLUS

Serial No.: 10/812,075

CN Benzamide, N-[cis-4-[[4-(dimethylamino)-6-methyl-2-pyrimidinyl]amino]cyclohexyl]-3-fluoro- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 771551-62-3 CAPLUS

CN Benzamide, N-[cis-4-[[4-(dimethylamino)-6-methyl-2-pyrimidinyl]amino]cyclohexyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 771551-64-5 CAPLUS

CN Benzamide, N-[cis-4-[[4-(dimethylamino)-6-methyl-2-pyrimidinyl]amino]cyclohexyl]-2-methoxy- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 771551-66-7 CAPLUS

CN Benzamide, N-[cis-4-[[4-(dimethylamino)-6-methyl-2-pyrimidinyl]amino]cyclohexyl]-4-methoxy- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 771551-68-9 CAPLUS

CN Benzamide, 3-cyano-N-[cis-4-[[4-(dimethylamino)-6-methyl-2-pyrimidinyl]amino]cyclohexyl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 771551-70-3 CAPLUS

CN Benzamide, 4-cyano-N-[cis-4-[[4-(dimethylamino)-6-methyl-2-pyrimidinyl]amino]cyclohexyl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 771551-72-5 CAPLUS


CN Benzamide, N-[cis-4-[[4-(dimethylamino)-6-methyl-2-pyrimidinyl]amino]cyclohexyl]-3-fluoro-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 771551-74-7 CAPLUS
 CN Benzamide, N-[cis-4-[[4-(dimethylamino)-6-methyl-2-pyrimidinyl]amino]cyclohexyl]-4-fluoro-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 771551-76-9 CAPLUS
 CN Benzamide, N-[cis-4-[[4-(dimethylamino)-6-methyl-2-pyrimidinyl]amino]cyclohexyl]-3-fluoro-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 771551-78-1 CAPLUS
 CN Benzamide, 3-chloro-N-[cis-4-[[4-(dimethylamino)-6-methyl-2-pyrimidinyl]amino]cyclohexyl]-4-fluoro- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771551-80-5 CAPLUS
 CN Benzamide, N-[cis-4-[[4-(dimethylamino)-6-methyl-2-pyrimidinyl]amino]cyclohexyl]-4-fluoro-3-methyl- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 771551-82-7 CAPLUS

CN Benzamide, N-[cis-4-[[4-(dimethylamino)-6-methyl-2-pyrimidinyl]amino]cyclohexyl]-3-fluoro-4-methyl- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 771551-84-9 CAPLUS

CN Benzamide, 3,5-dichloro-N-[cis-4-[[4-(dimethylamino)-6-methyl-2-pyrimidinyl]amino]cyclohexyl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 771551-86-1 CAPLUS

CN Benzamide, N-[cis-4-[[4-(dimethylamino)-6-methyl-2-pyrimidinyl]amino]cyclohexyl]-3-(trifluoromethoxy)- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 771551-88-3 CAPLUS

CN Benzamide, N-[cis-4-[[4-(dimethylamino)-6-methyl-2-pyrimidinyl]amino]cyclohexyl]-3,5-difluoro- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 771551-90-7 CAPLUS

CN Benzamide, 4-bromo-N-[cis-4-[[4-(dimethylamino)-6-methyl-2-pyrimidinyl]amino]cyclohexyl]-3-methyl- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 771551-92-9 CAPLUS

CN Benzamide, N-[cis-4-[[4-(dimethylamino)-6-methyl-2-pyrimidinyl]amino]cyclohexyl]-3-ethyl- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 771551-94-1 CAPLUS

CN Benzamide, N-[cis-4-[[4-(dimethylamino)-6-methyl-2-pyrimidinyl]amino]cyclohexyl]-4-ethoxy- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 771551-96-3 CAPLUS

CN Benzamide, N-[cis-4-[[4-(dimethylamino)-6-methyl-2-pyrimidinyl]amino]cyclohexyl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 771551-98-5 CAPLUS

CN Benzamide, 4-bromo-N-[cis-4-[[4-(dimethylamino)-6-methyl-2-pyrimidinyl]amino]cyclohexyl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 771552-00-2 CAPLUS

CN Benzamide, N-[cis-4-[[4-(dimethylamino)-6-methyl-2-pyrimidinyl]amino]cyclohexyl]-4-ethyl- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 771552-02-4 CAPLUS

CN Benzamide, N-[cis-4-[[4-(dimethylamino)-6-methyl-2-pyrimidinyl]amino]cyclohexyl]-3,5-diethoxy- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 771552-04-6 CAPLUS

CN Benzamide, N-[cis-4-[[4-(dimethylamino)-6-methyl-2-pyrimidinyl]amino]cyclohexyl]-3-ethoxy- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 771552-06-8 CAPLUS

CN Benzamide, N-[cis-4-[[4-(dimethylamino)-6-methyl-2-pyrimidinyl]amino]cyclohexyl]-3-(1-methylethoxy)- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 771552-14-8 CAPLUS

CN Benzamide, N-[cis-4-[[4-(dimethylamino)-6-methyl-2-pyrimidinyl]amino]cyclohexyl]-4-methoxy-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 771552-16-0 CAPLUS

CN Benzamide, 4-chloro-N-[cis-4-[[4-(dimethylamino)-6-methyl-2-pyrimidinyl]amino]cyclohexyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 771552-18-2 CAPLUS

CN Benzamide, N-[cis-4-[[4-(dimethylamino)-6-methyl-2-pyrimidinyl]amino]cyclohexyl]-3-methyl- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 771552-20-6 CAPLUS


CN Benzamide, N-[cis-4-[[4-(dimethylamino)-6-methyl-2-pyrimidinyl]amino]cyclohexyl]-3,4,5-trimethoxy- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771552-22-8 CAPLUS


CN Benzamide, N-[4-[[4-(dimethylamino)-6-methyl-2-pyrimidinyl]amino]cyclohexyl]-3-nitro- (9CI) (CA INDEX NAME)



RN 771552-26-2 CAPLUS

CN Benzamide, 3,4-dichloro-N-[cis-4-[[4-(dimethylamino)-6-methyl-2-pyrimidinyl]amino]cyclohexyl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 771553-00-5 CAPLUS

CN Benzamide, 3,4-dichloro-N-[cis-4-[[5-methyl-4-(methylamino)-2-pyrimidinyl]amino]cyclohexyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.




Serial No.: 10/812,075

RN 771555-36-3 CAPLUS

CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-3-methoxy-, monohydrochloride (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 771555-45-4 CAPLUS

CN Benzamide, 3-chloro-N-[cis-4-[[4-(dimethylamino)-6-methyl-2-pyrimidinyl]amino]cyclohexyl]-, monohydrochloride (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 771556-86-6 CAPLUS

CN Benzamide, 3-chloro-N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-4-fluoro-, monohydrochloride (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 771556-89-9 CAPLUS

CN Benzamide, 3-chloro-N-[cis-4-[[4-(dimethylamino)-6-methyl-2-pyrimidinyl]amino]cyclohexyl]-4-fluoro-, monohydrochloride (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 771556-90-2 CAPLUS

CN Benzamide, N-[cis-4-[[4-(dimethylamino)-6-ethyl-2-pyrimidinyl]amino]cyclohexyl]-3,4-difluoro-, monohydrochloride (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 771557-07-4 CAPLUS

CN Benzamide, N-[cis-4-[(4-amino-5-methyl-2-pyrimidinyl)amino]cyclohexyl]-3,5-bis(trifluoromethyl)-, monohydrochloride (9CI) (CA INDEX NAME)


Relative stereochemistry.



● HCl

RN 771557-21-2 CAPLUS
 CN Benzamide, N-[cis-4-[[4-methyl-6-(methylamino)-2-pyrimidinyl]amino]cyclohexyl]-4-(trifluoromethoxy)-, monohydrochloride
 (9CI) (CA INDEX NAME)

Relative stereochemistry.






● HCl

L25 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2004:875033 CAPLUS Full-text
 DOCUMENT NUMBER: 141:332214
 TITLE: Preparation of quinoline, tetrahydroquinazoline, and pyrimidine derivatives as MCH antagonist for treatment of CNS disorders
 INVENTOR(S): Sekiguchi, Yoshinori; Kanuma, Kosuke; Omodera, Katsunori; Busujima, Tsuyoshi; Tran, Thuy-Anh; Han, Sangdon; Casper, Martin; Kramer, Bryan A.; Semple, Graeme; Zou, Ning
 PATENT ASSIGNEE(S): Taisho Pharmaceutical Co. Ltd., Japan
 SOURCE: Eur. Pat. Appl., 586 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 3
 PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|--|------|----------|-----------------|----------|
| EP 1464335 | A2 | 20041006 | EP 2004-7651 | 20040330 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, | | | | |

IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK
 EP 1464335 A2 20041006 EP 2004-7651 20040330
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK
 PRIORITY APPLN. INFO.: US 2003-458530P P 20030331
 US 2003-495911P P 20030819
 US 2003-510186P P 20031009
 US 2003-530360P P 20031216
 EP 2004-7651 A 20040330

ED Entered STN: 22 Oct 2004
 GI



AB Title compds. I, II, and III [wherein R1 = (un)substituted (cyclo)alkyl, (cyclo)alkenyl, alkynyl, aryl; R2 = H, halo, OH, carboxy, carbamoyl, amino, (un)substituted alkyl, alkoxy; T = independently H, halo, OH, carboxy, carbamoyl, amino, cyano, NO2, alkenyl, alkynyl, cycloalkyl, (un)substituted alkyl, alkoxy; p = 0-5; L = aminocycloalkylideneamino, etc.; Y = bond, CH2, CO2, OCO, SO2, CO, CS, CONH, CSNH, etc.; with provisos; and pharmaceutically acceptable salts, hydrates, or solvates thereof] were prepared as antagonists of melanin concentrating hormone (MCH), an endogenous ligand of G-protein coupled receptors (GPCRs). Examples include solution and solid phase general synthetic methods and phys. data for nearly 3400 invention compds. In addition, all exemplified compds. were assayed using high throughput functional screening to detect intracellular Ca2+ concns. for accessing GPCR activation. For instance, reaction of 2,4-dichloro-6-methylpyrimidine with dimethylamine gave 2-chloro-4-(dimethylamino)-6-methylpyrimidine (40%), which was coupled with cis-(4-aminocyclohexyl)carbamic acid tert-Bu ester (60%). Deprotection (72%), amidation, and workup provided the benzamide IV•TFA. The latter demonstrated MCH antagonist activity with an IC50 value of 7.6 nM. Thus, pharmaceutical compns. comprising I are useful for the prophylaxis or treatment of improving memory function, sleeping and arousal, anxiety, depression, mood disorders, seizure, obesity, diabetes, appetite and eating disorders, cardiovascular disease, hypertension, dyslipidemia, myocardial

infarction, binge eating disorders including bulimia, anorexia, mental disorders including manic depression, schizophrenia, delirium, dementia, stress, cognitive disorders, attention deficit disorder, substance abuse disorders, and dyskinesias including Parkinson's disease, epilepsy, and addiction (no data). This is part III of three in a series covering the patent.

IT **771544-72-0P**, N-[cis-4-[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]-3,5-bis(trifluoromethyl)benzamide
771545-17-6P, N-[cis-4-[[4-(Dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino]cyclohexyl]benzamide **771545-22-3P**, N-[cis-4-[[4-(Dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino]cyclohexyl]-3-(trifluoromethyl)benzamide **771545-85-8P**, N-[cis-4-[[4-[Ethyl(methyl)amino]-5-methylpyrimidin-2-yl]amino]cyclohexyl]-3,4-difluorobenzamide **773141-41-6P**, 4-Chloro-N-[cis-4-[[4-methyl-6-(methylamino)pyrimidin-2-yl]amino]cyclohexyl]-3-(trifluoromethyl)benzamide **773141-63-2P**, 4-Chloro-N-[cis-4-[[4-dimethylamino-6-methylpyrimidin-2-yl]amino]cyclohexyl]-3-fluorobenzamide hydrochloride **773141-64-3P**, 3-Chloro-N-[cis-4-[[4-dimethylamino-6-methylpyrimidin-2-yl]amino]cyclohexyl]-5-fluorobenzamide hydrochloride **773141-65-4P**, N-[cis-4-[[4-Dimethylamino-6-methylpyrimidin-2-yl]amino]cyclohexyl]-3,4,5-trifluorobenzamide hydrochloride **773141-66-5P**, 3-Chloro-4-fluoro-N-[cis-4-[[5-methyl-4-methylaminopyrimidin-2-yl]amino]cyclohexyl]benzamide hydrochloride **773141-67-6P**, 4-Chloro-N-[cis-4-[[4-dimethylamino-5-methylpyrimidin-2-yl]amino]cyclohexyl]-3-fluorobenzamide hydrochloride **773141-68-7P**, 3-Chloro-N-[cis-4-[[4-dimethylamino-5-methylpyrimidin-2-yl]amino]cyclohexyl]-5-fluorobenzamide hydrochloride **773141-69-8P**, N-[cis-4-[[4-Dimethylamino-5-methylpyrimidin-2-yl]amino]cyclohexyl]-3,4,5-trifluorobenzamide hydrochloride **773141-70-1P**, N-[cis-4-[[4-Dimethylamino-5-methylpyrimidin-2-yl]amino]cyclohexyl]-3,5-difluorobenzamide hydrochloride **773141-72-3P**, N-[cis-4-[[4-Amino-5-methylpyrimidin-2-yl]amino]cyclohexyl]-3-chloro-4-fluorobenzamide hydrochloride **773141-79-0P**, 3-Chloro-N-[cis-4-[[4-dimethylamino-5-methylpyrimidin-2-yl]amino]cyclohexyl]-4-fluorobenzamide methanesulfonate **773142-96-4P**, N-[cis-4-[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]-3,4-difluorobenzamide **773143-00-3P**, N-[cis-4-[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]-4-(trifluoromethoxy)benzamide **773143-01-4P**, 3,4-Dichloro-N-[cis-4-[[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]benzamide **773143-05-8P**, 3,5-Dichloro-N-[cis-4-[[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]benzamide **773143-06-9P**, N-[cis-4-[[4-(Dimethylamino)-6-methylpyrimidin-2-yl]amino]cyclohexyl]-3,5-bis(trifluoromethyl)benzamide **773143-07-0P**, 4-Chloro-N-[cis-4-[[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]-3-(trifluoromethyl)benzamide **773143-09-2P**, 3-Chloro-N-[cis-4-[[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]-4-(trifluoromethoxy)benzamide **773143-10-5P**, N-[cis-4-[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]-4-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]benzamide **773143-16-1P**, 4-Chloro-N-[cis-4-[[4-dimethylamino-6-methylpyrimidin-2-yl]amino]cyclohexyl]-3-fluorobenzamide **773143-17-2P**, 3-Chloro-N-[cis-4-[[4-dimethylamino-6-methylpyrimidin-2-yl]amino]cyclohexyl]-5-fluorobenzamide **773143-19-4P**, N-[cis-4-[[4-Dimethylamino-6-methylpyrimidin-2-yl]amino]cyclohexyl]-3,4,5-trifluorobenzamide **773143-20-7P**, 3-Chloro-4-fluoro-N-[cis-4-[[5-methyl-4-methylaminopyrimidin-2-yl]amino]cyclohexyl]benzamide **773143-21-8P**, 4-Chloro-N-[cis-4-[[4-dimethylamino-5-methylpyrimidin-2-yl]amino]cyclohexyl]-3-fluorobenzamide **773143-22-9P**, 3-Chloro-N-[cis-4-[[4-

Serial No.: 10/812,075

dimethylamino-5-methylpyrimidin-2-yl)amino]cyclohexyl]-5-fluorobenzamide
773143-23-0P, N-[cis-4-[(4-Dimethylamino-5-methylpyrimidin-2-yl)amino]cyclohexyl]-3,4,5-trifluorobenzamide **773143-24-1P**,
N-[cis-4-[(4-Dimethylamino-5-methylpyrimidin-2-yl)amino]cyclohexyl]-3,5-difluorobenzamide

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(MCH antagonist; preparation of quinolines, quinazolines, and pyrimidines


as

MCH antagonist for treatment of CNS disorders)

RN 771544-72-0 CAPLUS

CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-3,5-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 771545-17-6 CAPLUS

CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5,6-dimethyl-2-pyrimidinyl]amino]cyclohexyl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 771545-22-3 CAPLUS

CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5,6-dimethyl-2-pyrimidinyl]amino]cyclohexyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 771545-85-8 CAPLUS

CN Benzamide, N-[cis-4-[[4-(ethylmethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-3,4-difluoro- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 773141-41-6 CAPLUS

CN Benzamide, 4-chloro-N-[cis-4-[[4-methyl-6-(methylamino)-2-pyrimidinyl]amino]cyclohexyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 773141-63-2 CAPLUS

CN Benzamide, 4-chloro-N-[cis-4-[[4-(dimethylamino)-6-methyl-2-pyrimidinyl]amino]cyclohexyl]-3-fluoro-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 773141-64-3 CAPLUS

Serial No.: 10/812,075

CN Benzamide, 3-chloro-N-[cis-4-[[4-(dimethylamino)-6-methyl-2-pyrimidinyl]amino]cyclohexyl]-5-fluoro-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 773141-65-4 CAPLUS

CN Benzamide, N-[cis-4-[[4-(dimethylamino)-6-methyl-2-pyrimidinyl]amino]cyclohexyl]-3,4,5-trifluoro-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 773141-66-5 CAPLUS

CN Benzamide, 3-chloro-4-fluoro-N-[cis-4-[[5-methyl-4-(methylamino)-2-pyrimidinyl]amino]cyclohexyl]-, monohydrochloride (9CI) (CA INDEX NAME)


Relative stereochemistry.



● HCl


RN 773141-67-6 CAPLUS
 CN Benzamide, 4-chloro-N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-3-fluoro-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 773141-68-7 CAPLUS
 CN Benzamide, 3-chloro-N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-5-fluoro-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 773141-69-8 CAPLUS
 CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-3,4,5-trifluoro-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 773141-70-1 CAPLUS

CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-3,5-difluoro-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 773141-72-3 CAPLUS

CN Benzamide, N-[cis-4-[[4-amino-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-3-chloro-4-fluoro-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 773141-79-0 CAPLUS

CN Benzamide, 3-chloro-N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-4-fluoro-, monomethanesulfonate (9CI) (CA


INDEX NAME)

CM 1

CRN 771551-22-5

CMF C20 H25 Cl F N5 O


Relative stereochemistry.



CM 2

CRN 75-75-2


CMF C H4 O3 S



RN 773142-96-4 CAPLUS

CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-3,4-difluoro- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 773143-00-3 CAPLUS

CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-4-(trifluoromethoxy)- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 773143-01-4 CAPLUS

CN Benzamide, 3,4-dichloro-N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 773143-05-8 CAPLUS

CN Benzamide, 3,5-dichloro-N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 773143-06-9 CAPLUS

CN Benzamide, N-[cis-4-[[4-(dimethylamino)-6-methyl-2-pyrimidinyl]amino]cyclohexyl]-3,5-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 773143-07-0 CAPLUS

CN Benzamide, 4-chloro-N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 773143-09-2 CAPLUS

CN Benzamide, 3-chloro-N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-4-(trifluoromethoxy)- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 773143-10-5 CAPLUS

CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-4-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 773143-16-1 CAPLUS

CN Benzamide, 4-chloro-N-[cis-4-[[4-(dimethylamino)-6-methyl-2-pyrimidinyl]amino]cyclohexyl]-3-fluoro- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 773143-17-2 CAPLUS

CN Benzamide, 3-chloro-N-[cis-4-[[4-(dimethylamino)-6-methyl-2-pyrimidinyl]amino]cyclohexyl]-5-fluoro- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 773143-19-4 CAPLUS

CN Benzamide, N-[cis-4-[[4-(dimethylamino)-6-methyl-2-pyrimidinyl]amino]cyclohexyl]-3,4,5-trifluoro- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 773143-20-7 CAPLUS

CN Benzamide, 3-chloro-4-fluoro-N-[cis-4-[[5-methyl-4-(methylamino)-2-pyrimidinyl]amino]cyclohexyl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 773143-21-8 CAPLUS

CN Benzamide, 4-chloro-N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-3-fluoro- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 773143-22-9 CAPLUS

CN Benzamide, 3-chloro-N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-5-fluoro- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 773143-23-0 CAPLUS

CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-3,4,5-trifluoro- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 773143-24-1 CAPLUS

CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-3,5-difluoro- (9CI) (CA INDEX NAME)

Relative stereochemistry.



L25 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2004:875032 CAPLUS Full-text

DOCUMENT NUMBER: 141:350191




TITLE: Preparation of quinoline, tetrahydroquinazoline, and pyrimidine derivatives as MCH antagonist for treatment of CNS disorders

INVENTOR(S): Sekiguchi, Yoshinori; Kanuma, Kosuke
; Omodera, Katsunori; Busujima, Tsuyoshi; Tran, Thuy-Anh; Han, Sangdon; Casper, Martin; Kramer, Bryan A.; Semple, Graeme; Zou, Ning

PATENT ASSIGNEE(S): Taisho Pharmaceutical Co. Ltd., Japan
 SOURCE: Eur. Pat. Appl., 586 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 3
 PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|-----------------|------------|
| EP 1464335 | A2 | 20041006 | EP 2004-7651 | 20040330 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK | | | | |
| EP 1464335 | A2 | 20041006 | EP 2004-7651 | 20040330 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK | | | | |
| PRIORITY APPLN. INFO.: | | | US 2003-458530P | P 20030331 |
| | | | US 2003-495911P | P 20030819 |
| | | | US 2003-510186P | P 20031009 |
| | | | US 2003-530360P | P 20031216 |
| | | | EP 2004-7651 | A 20040330 |

ED Entered STN: 22 Oct 2004
 GI




AB Title compds. I, II, and III [wherein R1 = (un)substituted (cyclo)alkyl, (cyclo)alkenyl, alkynyl, aryl; R2 = H, halo, OH, carboxy, carbamoyl, amino, (un)substituted alkyl, alkoxy; T = independently H, halo, OH, carboxy, carbamoyl, amino, cyano, NO₂, alkenyl, alkynyl, cycloalkyl, (un)substituted alkyl, alkoxy; p = 0-5; L = aminocycloalkylideneamino, etc.; Y = bond, CH₂, CO₂, OCO, SO₂, CO, CS, CONH, CSNH, etc.; with provisos; and pharmaceutically acceptable salts, hydrates, or solvates thereof] were prepared as antagonists of melanin concentrating hormone (MCH), an endogenous ligand of G-protein coupled receptors (GPCRs). Examples include solution and solid phase general

synthetic methods and phys. data for nearly 3400 invention compds. In addition, all exemplified compds. were assayed using high throughput functional screening to detect intracellular Ca^{2+} concns. for accessing GPCR activation. For instance, reaction of 2,4-dichloro-6-methylpyrimidine with dimethylamine gave 2-chloro-4-(dimethylamino)-6-methylpyrimidine (40%), which was coupled with cis-(4-aminocyclohexyl)carbamic acid tert-Bu ester (60%). Deprotection (72%), amidation, and workup provided the benzamide IV•TFA. The latter demonstrated MCH antagonist activity with an IC_{50} value of 7.6 nM. Thus, pharmaceutical compns. comprising I are useful for the prophylaxis or treatment of improving memory function, sleeping and arousal, anxiety, depression, mood disorders, seizure, obesity, diabetes, appetite and eating disorders, cardiovascular disease, hypertension, dyslipidemia, myocardial infarction, binge eating disorders including bulimia, anorexia, mental disorders including manic depression, schizophrenia, delirium, dementia, stress, cognitive disorders, attention deficit disorder, substance abuse disorders, and dyskinesias including Parkinson's disease, epilepsy, and addiction (no data). This is part II of three in a series covering the patent.


IT **771544-72-0P**, N-[cis-4-[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]-3,5-bis(trifluoromethyl)benzamide
771545-85-8P, N-[cis-4-[[4-[Ethyl(methyl)amino]-5-methylpyrimidin-2-yl]amino]cyclohexyl]-3,4-difluorobenzamide
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (intermediate; preparation of quinolines, quinazolines, and pyrimidines as melanin-concentrating hormone antagonist for treatment of CNS disorders)
 RN 771544-72-0 CAPLUS
 CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-3,5-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771545-85-8 CAPLUS
 CN Benzamide, N-[cis-4-[[4-(ethylmethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-3,4-difluoro- (9CI) (CA INDEX NAME)

Relative stereochemistry.



IT 771543-92-1P, N-[cis-4-[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]-3,4-difluorobenzamide hydrochloride
 771543-93-2P, 3-Chloro-N-[cis-4-[[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]benzamide hydrochloride
 771543-95-4P, N-[cis-4-[[4-(Dimethylamino)-6-methylpyrimidin-2-yl]amino]cyclohexyl]-3-methylbenzamide trifluoroacetate
 771544-42-4P, N-[cis-4-[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]-3-methylbenzamide 771544-43-5P,
 N-[cis-4-[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]-3-methoxybenzamide 771544-44-6P, N-[cis-4-[[4-(Dimethylamino)-6-methylpyrimidin-2-yl]amino]cyclohexyl]-3-methoxybenzamide
 771544-45-7P, N-[cis-4-[[4-(Dimethylamino)-6-methylpyrimidin-2-yl]amino]cyclohexyl]-4-methylbenzamide 771544-46-8P,
 4-Chloro-N-[cis-4-[[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino]cyclohexyl]benzamide 771544-47-9P, 3-Chloro-N-[cis-4-[[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino]cyclohexyl]benzamide
 771544-48-0P, N-[cis-4-[[4-(Dimethylamino)-6-methylpyrimidin-2-yl]amino]cyclohexyl]-3,4-difluorobenzamide 771544-49-1P,
 N-[cis-4-[[4-(Dimethylamino)-6-methylpyrimidin-2-yl]amino]cyclohexyl]-4-(trifluoromethoxy)benzamide 771544-50-4P, N-[cis-4-[[4-(Dimethylamino)-6-methylpyrimidin-2-yl]amino]cyclohexyl]-4-fluorobenzamide
 771544-68-4P, N-[cis-4-[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]-3,5-bis(trifluoromethyl)benzamide hydrochloride
 771544-99-1P, 3,5-Dibromo-N-[cis-4-[[5-methyl-4-(methylamino)pyrimidin-2-yl]amino]cyclohexyl]benzamide trifluoroacetate
 771545-01-8P, 3-Fluoro-N-[cis-4-[[5-methyl-4-(methylamino)pyrimidin-2-yl]amino]cyclohexyl]-5-(trifluoromethyl)benzamide trifluoroacetate 771545-03-0P, N-[cis-4-[[5-Methyl-4-(methylamino)pyrimidin-2-yl]amino]cyclohexyl]-4-(trifluoromethoxy)benzamide trifluoroacetate 771545-04-1P,
 N-[cis-4-[[5-Methyl-4-(methylamino)pyrimidin-2-yl]amino]cyclohexyl]-3,5-bis(trifluoromethyl)benzamide hydrochloride 771545-06-3P
 771545-08-5P, 3,4-Difluoro-N-[cis-4-[[4-(isopropylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]benzamide trifluoroacetate
 771545-10-9P 771545-12-1P, 3,4-Difluoro-N-[cis-4-[[5-methyl-4-(methylamino)pyrimidin-2-yl]amino]cyclohexyl]benzamide trifluoroacetate 771545-18-7P, N-[cis-4-[[4-(Dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino]cyclohexyl]benzamide trifluoroacetate
 771545-23-4P 771545-80-3P, N-[cis-4-[[4-(Dimethylamino)-5-ethylpyrimidin-2-yl]amino]cyclohexyl]-3,4-difluorobenzamide
 771545-83-6P, N-[cis-4-[[4-[Ethyl(methyl)amino]-5-methylpyrimidin-2-yl]amino]cyclohexyl]-3,4-difluorobenzamide hydrochloride
 771546-31-7P, N-[cis-4-[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]-3-methylbenzamide hydrochloride 771546-33-9P
 , N-[cis-4-[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]-3-(trifluoromethoxy)benzamide hydrochloride 771546-35-1P,
 N-[cis-4-[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]-4-(trifluoromethoxy)benzamide hydrochloride 771546-37-3P,
 3-Chloro-N-[cis-4-[[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]-4-(trifluoromethoxy)benzamide hydrochloride
 771546-39-5P, 4-Chloro-N-[cis-4-[[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]-3-(trifluoromethyl)benzamide hydrochloride 771546-41-9P, 3,5-Dichloro-N-[cis-4-[[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]benzamide hydrochloride 771546-43-1P, 3,4-Dichloro-N-[cis-4-[[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]benzamide hydrochloride 771546-47-5P, N-[cis-4-[[4-(Dimethylamino)-5-

methylpyrimidin-2-yl]amino]cyclohexyl]-2-(methylsulfonyl)benzamide
771546-49-7P, N-[cis-4-[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]-3-(methylsulfonyl)benzamide **771546-51-1P**,
 N-[cis-4-[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]-4-(methylsulfonyl)benzamide **771546-53-3P**, Methyl
 2-[[[cis-4-[[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]amino]carbonyl]benzoate **771546-55-5P**, Methyl
 3-[[[cis-4-[[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]amino]carbonyl]benzoate **771546-57-7P**,
 2-[[[cis-4-[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]amino]carbonyl]benzoic acid hydrochloride
771546-59-9P, 3-[[[cis-4-[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]amino]carbonyl]benzoic acid hydrochloride
771546-61-3P, N-[cis-4-[[4-(Dimethylamino)-6-methylpyrimidin-2-yl]amino]cyclohexyl]-3,4-difluorobenzamide hydrochloride
771546-63-5P, N-[cis-4-[[4-(Dimethylamino)-6-methylpyrimidin-2-yl]amino]cyclohexyl]-3,5-bis(trifluoromethyl)benzamide hydrochloride
771546-65-7P, N-[cis-4-[[4-(Dimethylamino)-6-methylpyrimidin-2-yl]amino]cyclohexyl]-4-(trifluoromethoxy)benzamide hydrochloride
771546-67-9P, 3-Chloro-N-[cis-4-[[4-(Dimethylamino)-6-methylpyrimidin-2-yl]amino]cyclohexyl]-4-(trifluoromethoxy)benzamide
 hydrochloride **771546-69-1P**, 4-Chloro-N-[cis-4-[[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino]cyclohexyl]benzamide
 hydrochloride **771546-71-5P**, 3,4-Dichloro-N-[cis-4-[[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino]cyclohexyl]benzamide
 hydrochloride **771546-73-7P**, N-[cis-4-[[4-(Dimethylamino)-6-methylpyrimidin-2-yl]amino]cyclohexyl]-3,5-dimethoxybenzamide
771546-77-1P, N-[cis-4-[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]-4-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]benzamide hydrochloride **771546-79-3P**,
 3-Bromo-4-chloro-N-[cis-4-[[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]benzamide hydrochloride **771549-06-5P**,
 N-[cis-4-[[4-(Dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino]cyclohexyl]-3-methoxybenzamide **771549-30-5P**, 3-Cyano-N-[cis-4-[[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino]cyclohexyl]benzamide
771549-32-7P, N-[cis-4-[[4-(Dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino]cyclohexyl]-3-methylbenzamide **771549-34-9P**,
 3-Chloro-N-[cis-4-[[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino]cyclohexyl]benzamide **771549-36-1P**, 3-Bromo-N-[cis-4-[[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino]cyclohexyl]benzamide
771549-38-3P, N-[cis-4-[[4-(Dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino]cyclohexyl]-3,5-dimethoxybenzamide **771549-40-7P**,
 N-[cis-4-[[4-(Dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino]cyclohexyl]-3,5-bis(trifluoromethyl)benzamide **771549-42-9P**,
 3,4-Dichloro-N-[cis-4-[[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino]cyclohexyl]benzamide **771549-44-1P**, N-[cis-4-[[4-(Dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino]cyclohexyl]-4-(trifluoromethoxy)benzamide **771549-46-3P**, 4-Cyano-N-[cis-4-[[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino]cyclohexyl]benzamide
771549-48-5P, N-[cis-4-[[4-(Dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino]cyclohexyl]-4-methylbenzamide **771549-50-9P**,
 N-[cis-4-[[4-(Dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino]cyclohexyl]-4-fluorobenzamide **771549-52-1P**, 4-Chloro-N-[cis-4-[[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino]cyclohexyl]benzamide
771549-54-3P, N-[cis-4-[[4-(Dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino]cyclohexyl]-2-methoxybenzamide **771549-56-5P**,
 4-Bromo-N-[cis-4-[[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino]cyclohexyl]benzamide **771549-58-7P**, N-[cis-4-[[4-(Dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino]cyclohexyl]-4-(trifluoromethyl)benzamide **771549-60-1P**, N-[cis-4-[[4-

(Dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino]cyclohexyl]-4-ethoxybenzamide **771549-62-3P**, 4-Bromo-N-[cis-4-[[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino]cyclohexyl]-3-methylbenzamide **771549-64-5P**, N-[cis-4-[[4-(Dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino]cyclohexyl]-3-fluoro-4-methylbenzamide **771549-66-7P**, N-[cis-4-[[4-(Dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino]cyclohexyl]-4-fluoro-3-methylbenzamide **771549-68-9P**, N-[cis-4-[[4-(Dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino]cyclohexyl]-3-ethylbenzamide **771549-70-3P**, N-[cis-4-[[4-(Dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino]cyclohexyl]-3-(trifluoromethoxy)benzamide **771549-78-1P**, N-[cis-4-[[4-(Dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino]cyclohexyl]-3,5-diethoxybenzamide **771549-80-5P**, N-[cis-4-[[4-(Dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino]cyclohexyl]-3-ethoxybenzamide **771549-82-7P**, N-[cis-4-[[4-(Dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino]cyclohexyl]-3-isopropoxybenzamide **771549-86-1P**, N-[cis-4-[[4-(Dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino]cyclohexyl]-3,4-difluorobenzamide **771550-50-6P**, N-[cis-4-[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]-3-(trifluoromethyl)benzamide **771550-52-8P**, N-[cis-4-[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]-3-fluorobenzamide **771550-54-0P**, 3-Bromo-N-[cis-4-[[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]benzamide **771550-56-2P**, N-[cis-4-[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]-4-fluorobenzamide **771550-58-4P**, N-[cis-4-[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]-3,5-dimethoxybenzamide **771550-60-8P**, N-[cis-4-[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]-2,4-difluorobenzamide **771550-62-0P**, N-[cis-4-[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]-2,5-difluorobenzamide **771550-64-2P**, N-[cis-4-[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]-2,3,4-trifluorobenzamide **771550-66-4P**, N-[cis-4-[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]benzamide **771550-68-6P**, 4-tert-Butyl-N-[cis-4-[[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]benzamide **771550-70-0P**, 4-Butyl-N-[cis-4-[[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]benzamide **771550-72-2P**, 4-Chloro-N-[cis-4-[[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]benzamide **771550-74-4P**, 3-Cyano-N-[cis-4-[[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]benzamide **771550-76-6P**, 4-Cyano-N-[cis-4-[[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]benzamide **771550-78-8P**, N-[cis-4-[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]-2-methoxybenzamide **771550-80-2P**, 4-Bromo-N-[cis-4-[[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]benzamide **771550-82-4P**, N-[cis-4-[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]-4-(trifluoromethyl)benzamide **771550-84-6P**, N-[cis-4-[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]-4-methoxybenzamide **771550-86-8P**, 2-Bromo-N-[cis-4-[[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]benzamide **771550-88-0P**, 2-Chloro-N-[cis-4-[[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]benzamide **771550-90-4P**, N-[cis-4-[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]-2-fluorobenzamide **771550-92-6P**, N-[cis-4-[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]-2-methylbenzamide **771550-94-8P**, N-[cis-4-[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]-2-(trifluoromethyl)benzamide **771550-96-0P**, N-[cis-4-[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]-4-fluoro-3-(trifluoromethyl)benzamide **771550-98-2P**, 4-Bromo-N-[cis-4-[[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]-3-methylbenzamide **771551-00-9P**, N-[cis-4-[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]-4-

ethoxybenzamide **771551-02-1P**, 3-(Dimethylamino)-N-[cis-4-[[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]benzamide
771551-04-3P, N-[cis-4-[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]-4-fluoro-3-methylbenzamide **771551-06-5P**,
N-[cis-4-[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]-3-fluoro-4-methylbenzamide **771551-08-7P**, N-[cis-4-[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]-3-ethylbenzamide
771551-12-3P, N-[cis-4-[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]-3-ethoxybenzamide **771551-14-5P**,
N-[cis-4-[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]-3-isopropoxybenzamide **771551-16-7P**, N-[cis-4-[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]-3,5-diethoxybenzamide
771551-18-9P, N-[cis-4-[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]-3-fluoro-5-(trifluoromethyl)benzamide
771551-20-3P, N-[cis-4-[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]-3-fluoro-4-(trifluoromethyl)benzamide
771551-22-5P, 3-Chloro-N-[cis-4-[[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]-4-fluorobenzamide
771551-24-7P, 3,5-Dibromo-N-[cis-4-[[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]benzamide **771551-26-9P**,
N-[cis-4-[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]-3,5-dimethylbenzamide **771551-28-1P**, 4-Chloro-N-[cis-4-[[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]-3-methylbenzamide
771551-30-5P, N-[cis-4-[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]-4-methoxy-3-(trifluoromethyl)benzamide
771551-32-7P, N-[cis-4-[[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]-4-methylbenzamide **771551-34-9P**,
3-Chloro-N-[cis-4-[[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl]benzamide **771551-56-5P**, N-[cis-4-[[4-(Dimethylamino)-6-methylpyrimidin-2-yl]amino]cyclohexyl]benzamide
771551-58-7P, 4-Butyl-N-[cis-4-[[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino]cyclohexyl]benzamide **771551-60-1P**,
N-[cis-4-[[4-(Dimethylamino)-6-methylpyrimidin-2-yl]amino]cyclohexyl]-3-fluorobenzamide **771551-62-3P**, N-[cis-4-[[4-(Dimethylamino)-6-methylpyrimidin-2-yl]amino]cyclohexyl]-3-(trifluoromethyl)benzamide
771551-64-5P, N-[cis-4-[[4-(Dimethylamino)-6-methylpyrimidin-2-yl]amino]cyclohexyl]-2-methoxybenzamide **771551-66-7P**,
N-[cis-4-[[4-(Dimethylamino)-6-methylpyrimidin-2-yl]amino]cyclohexyl]-4-methoxybenzamide **771551-68-9P**, 3-Cyano-N-[cis-4-[[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino]cyclohexyl]benzamide
771551-70-3P, 4-Cyano-N-[cis-4-[[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino]cyclohexyl]benzamide **771551-72-5P**,
N-[cis-4-[[4-(Dimethylamino)-6-methylpyrimidin-2-yl]amino]cyclohexyl]-3-fluoro-4-(trifluoromethyl)benzamide **771551-74-7P**,
N-[cis-4-[[4-(Dimethylamino)-6-methylpyrimidin-2-yl]amino]cyclohexyl]-4-fluoro-3-(trifluoromethyl)benzamide **771551-76-9P**,
N-[cis-4-[[4-(Dimethylamino)-6-methylpyrimidin-2-yl]amino]cyclohexyl]-3-fluoro-5-(trifluoromethyl)benzamide **771551-78-1P**,
3-Chloro-N-[cis-4-[[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino]cyclohexyl]-4-fluorobenzamide **771551-80-5P**,
N-[cis-4-[[4-(Dimethylamino)-6-methylpyrimidin-2-yl]amino]cyclohexyl]-4-fluoro-3-methylbenzamide **771551-82-7P**, N-[cis-4-[[4-(Dimethylamino)-6-methylpyrimidin-2-yl]amino]cyclohexyl]-3-fluoro-4-methylbenzamide
771551-84-9P, 3,5-Dichloro-N-[cis-4-[[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino]cyclohexyl]benzamide
771551-86-1P, N-[cis-4-[[4-(Dimethylamino)-6-methylpyrimidin-2-yl]amino]cyclohexyl]-3-(trifluoromethoxy)benzamide **771551-88-3P**,
N-[cis-4-[[4-(Dimethylamino)-6-methylpyrimidin-2-yl]amino]cyclohexyl]-3,5-difluorobenzamide **771551-90-7P**, 4-Bromo-N-[cis-4-[[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino]cyclohexyl]-3-methylbenzamide

771551-92-9P, N-[cis-4-[[4-(Dimethylamino)-6-methylpyrimidin-2-yl]amino]cyclohexyl]-3-ethylbenzamide 771551-94-1P, N-[cis-4-[[4-(Dimethylamino)-6-methylpyrimidin-2-yl]amino]cyclohexyl]-4-ethoxybenzamide 771551-96-3P, N-[cis-4-[[4-(Dimethylamino)-6-methylpyrimidin-2-yl]amino]cyclohexyl]-4-(trifluoromethyl)benzamide 771551-98-5P, 4-Bromo-N-[cis-4-[[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino]cyclohexyl]benzamide 771552-00-2P, N-[cis-4-[[4-(Dimethylamino)-6-methylpyrimidin-2-yl]amino]cyclohexyl]-4-ethylbenzamide 771552-02-4P, N-[cis-4-[[4-(Dimethylamino)-6-methylpyrimidin-2-yl]amino]cyclohexyl]-3,5-diethoxybenzamide 771552-04-6P, N-[cis-4-[[4-(Dimethylamino)-6-methylpyrimidin-2-yl]amino]cyclohexyl]-3-ethoxybenzamide 771552-06-8P, N-[cis-4-[[4-(Dimethylamino)-6-methylpyrimidin-2-yl]amino]cyclohexyl]-3-isopropoxybenzamide 771552-14-8P, N-[cis-4-[[4-(Dimethylamino)-6-methylpyrimidin-2-yl]amino]cyclohexyl]-4-methoxy-3-(trifluoromethyl)benzamide 771552-16-0P, 4-Chloro-N-[cis-4-[[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino]cyclohexyl]-3-(trifluoromethyl)benzamide 771552-18-2P, N-[cis-4-[[4-(Dimethylamino)-6-methylpyrimidin-2-yl]amino]cyclohexyl]-3-methylbenzamide 771552-20-6P, N-[cis-4-[[4-(Dimethylamino)-6-methylpyrimidin-2-yl]amino]cyclohexyl]-3,4,5-trimethoxybenzamide 771552-22-8P, N-[4-[[4-(Dimethylamino)-6-methylpyrimidin-2-yl]amino]cyclohexyl]-3-nitrobenzamide 771552-26-2P, 3,4-Dichloro-N-[cis-4-[[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino]cyclohexyl]benzamide 771553-00-5P, 3,4-Dichloro-N-[cis-4-[[5-methyl-4-(methylamino)pyrimidin-2-yl]amino]cyclohexyl]benzamide 771555-36-3P, N-[cis-4-(4-Dimethylamino-5-methylpyrimidin-2-ylamino)cyclohexyl]-3-methoxybenzamide hydrochloride 771555-45-4P, 3-Chloro-N-[cis-4-(4-dimethylamino-6-methylpyrimidin-2-ylamino)cyclohexyl]benzamide hydrochloride 771556-86-6P, 3-Chloro-N-[cis-4-(4-dimethylamino-5-methylpyrimidin-2-ylamino)cyclohexyl]-4-fluorobenzamide hydrochloride 771556-89-9P, 3-Chloro-N-[cis-4-(4-dimethylamino-6-methylpyrimidin-2-ylamino)cyclohexyl]-4-fluorobenzamide hydrochloride 771556-90-2P, N-[cis-4-(4-Dimethylamino-6-ethylpyrimidin-2-ylamino)cyclohexyl]-3,4-difluorobenzamide hydrochloride 771557-07-4P, N-[cis-4-[[4-Amino-5-methylpyrimidin-2-yl]amino]cyclohexyl]-3,5-bis(trifluoromethyl)benzamide hydrochloride 771557-21-2P, N-[cis-4-[[4-Methyl-6-(methylamino)pyrimidin-2-yl]amino]cyclohexyl]-4-(trifluoromethoxy)benzamide hydrochloride


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(melanin-concentrating hormone antagonist; preparation of quinolines, quinazolines, and pyrimidines as melanin-concentrating hormone antagonist for treatment of CNS disorders)

RN 771543-92-1 CAPLUS

CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-3,4-difluoro-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 771543-93-2 CAPLUS

CN Benzamide, 3-chloro-N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 771543-95-4 CAPLUS


CN Benzamide, N-[cis-4-[[4-(dimethylamino)-6-methyl-2-pyrimidinyl]amino]cyclohexyl]-3-methyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 771552-18-2


CMF C21 H29 N5 O

Relative stereochemistry.




CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 771544-42-4 CAPLUS
CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-3-methyl- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 771544-43-5 CAPLUS
CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-3-methoxy- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771544-44-6 CAPLUS
CN Benzamide, N-[cis-4-[[4-(dimethylamino)-6-methyl-2-pyrimidinyl]amino]cyclohexyl]-3-methoxy- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 771544-45-7 CAPLUS

CN Benzamide, N-[cis-4-[[4-(dimethylamino)-6-methyl-2-pyrimidinyl]amino]cyclohexyl]-4-methyl- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 771544-46-8 CAPLUS

CN Benzamide, 4-chloro-N-[cis-4-[[4-(dimethylamino)-6-methyl-2-pyrimidinyl]amino]cyclohexyl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 771544-47-9 CAPLUS

CN Benzamide, 3-chloro-N-[cis-4-[[4-(dimethylamino)-6-methyl-2-pyrimidinyl]amino]cyclohexyl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 771544-48-0 CAPLUS

CN Benzamide, N-[cis-4-[[4-(dimethylamino)-6-methyl-2-pyrimidinyl]amino]cyclohexyl]-3,4-difluoro- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 771544-49-1 CAPLUS

CN Benzamide, N-[cis-4-[[4-(dimethylamino)-6-methyl-2-pyrimidinyl]amino]cyclohexyl]-4-(trifluoromethoxy)- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 771544-50-4 CAPLUS

CN Benzamide, N-[cis-4-[[4-(dimethylamino)-6-methyl-2-pyrimidinyl]amino]cyclohexyl]-4-fluoro- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 771544-68-4 CAPLUS

CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-3,5-bis(trifluoromethyl)-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 771544-99-1 CAPLUS
 CN Benzamide, 3,5-dibromo-N-[cis-4-[[5-methyl-4-(methylamino)-2-pyrimidinyl]amino]cyclohexyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 771544-98-0
 CMF C19 H23 Br2 N5 O

Relative stereochemistry.



CM 2

CRN 76-05-1
 CMF C2 H F3 O2




RN 771545-01-8 CAPLUS
 CN Benzamide, 3-fluoro-N-[cis-4-[[5-methyl-4-(methylamino)-2-pyrimidinyl]amino]cyclohexyl]-5-(trifluoromethyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 771545-00-7
CMF C20 H23 F4 N5 O

Relative stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 771545-03-0 CAPLUS
CN Benzamide, N-[cis-4-[[5-methyl-4-(methylamino)-2-pyrimidinyl]amino]cyclohexyl]-4-(trifluoromethoxy)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 771545-02-9
CMF C20 H24 F3 N5 O2

Relative stereochemistry.




CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 771545-04-1 CAPLUS
 CN Benzamide, N-[cis-4-[[5-methyl-4-(methylamino)-2-pyrimidinyl]amino]cyclohexyl]-3,5-bis(trifluoromethyl)-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl


RN 771545-06-3 CAPLUS
 CN Benzamide, N-[cis-4-[[4-(ethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-3,4-difluoro-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 771545-05-2

CMF C20 H25 F2 N5 O


Relative stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 771545-08-5 CAPLUS


CN Benzamide, 3,4-difluoro-N-[cis-4-[[5-methyl-4-[(1-methylethyl)amino]-2-pyrimidinyl]amino]cyclohexyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 771545-07-4

CMF C21 H27 F2 N5 O


Relative stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 771545-10-9 CAPLUS


CN Benzamide, N-[cis-4-[[4-(cyclopropylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-3,4-difluoro-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 771545-09-6

CMF C21 H25 F2 N5 O


Relative stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 771545-12-1 CAPLUS


CN Benzamide, 3,4-difluoro-N-[cis-4-[[5-methyl-4-(methylamino)-2-pyrimidinyl]amino]cyclohexyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 771545-11-0


CMF C19 H23 F2 N5 O

Relative stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 771545-18-7 CAPLUS
CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5,6-dimethyl-2-pyrimidinyl]amino]cyclohexyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 771545-17-6
CMF C21 H29 N5 O

Relative stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 771545-23-4 CAPLUS
CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5,6-dimethyl-2-pyrimidinyl]amino]cyclohexyl]-3-(trifluoromethyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 771545-22-3
CMF C22 H28 F3 N5 O


Relative stereochemistry.



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 771545-80-3 CAPLUS

CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5-ethyl-2-pyrimidinyl]amino]cyclohexyl]-3,4-difluoro- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 771545-83-6 CAPLUS

CN Benzamide, N-[cis-4-[[4-(ethylmethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-3,4-difluoro-, monohydrochloride (9CI) (CA INDEX NAME)


Relative stereochemistry.



● HCl

RN 771546-31-7 CAPLUS
 CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-3-methyl-, monohydrochloride (9CI) (CA INDEX NAME)


Relative stereochemistry.



● HCl

RN 771546-33-9 CAPLUS
 CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-3-(trifluoromethoxy)-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 771546-35-1 CAPLUS
 CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-4-(trifluoromethoxy)-, monohydrochloride

(9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 771546-37-3 CAPLUS

CN Benzamide, 3-chloro-N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-4-(trifluoromethoxy)-, monohydrochloride
(9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 771546-39-5 CAPLUS

CN Benzamide, 4-chloro-N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-3-(trifluoromethyl)-, monohydrochloride
(9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 771546-41-9 CAPLUS

CN Benzamide, 3,5-dichloro-N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-, monohydrochloride (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 771546-43-1 CAPLUS

CN Benzamide, 3,4-dichloro-N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-, monohydrochloride (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 771546-47-5 CAPLUS

CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-2-(methylsulfonyl)- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 771546-49-7 CAPLUS

Serial No.: 10/812,075

CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-3-(methylsulfonyl)- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 771546-51-1 CAPLUS

CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-4-(methylsulfonyl)- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 771546-53-3 CAPLUS

CN Benzoic acid, 2-[[[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]amino]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 771546-55-5 CAPLUS

CN Benzoic acid, 3-[[[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]amino]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 771546-57-7 CAPLUS

CN Benzoic acid, 2-[[[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]amino]carbonyl]-, monohydrochloride (9CI)
(CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 771546-59-9 CAPLUS

CN Benzoic acid, 3-[[[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]amino]carbonyl]-, monohydrochloride (9CI)
(CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 771546-61-3 CAPLUS

CN Benzamide, N-[cis-4-[[4-(dimethylamino)-6-methyl-2-pyrimidinyl]amino]cyclohexyl]-3,4-difluoro-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 771546-63-5 CAPLUS

CN Benzamide, N-[cis-4-[[4-(dimethylamino)-6-methyl-2-pyrimidinyl]amino]cyclohexyl]-3,5-bis(trifluoromethyl)-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 771546-65-7 CAPLUS

CN Benzamide, N-[cis-4-[[4-(dimethylamino)-6-methyl-2-pyrimidinyl]amino]cyclohexyl]-4-(trifluoromethoxy)-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 771546-67-9 CAPLUS

CN Benzamide, 3-chloro-N-[cis-4-[[4-(dimethylamino)-6-methyl-2-pyrimidinyl]amino]cyclohexyl]-4-(trifluoromethoxy)-, monohydrochloride

(9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 771546-69-1 CAPLUS

CN Benzamide, 4-chloro-N-[cis-4-[[4-(dimethylamino)-6-methyl-2-pyrimidinyl]amino]cyclohexyl]-, monohydrochloride (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 771546-71-5 CAPLUS

CN Benzamide, 3,4-dichloro-N-[cis-4-[[4-(dimethylamino)-6-methyl-2-pyrimidinyl]amino]cyclohexyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 771546-73-7 CAPLUS

Serial No.: 10/812,075

CN Benzamide, N-[cis-4-[[4-(dimethylamino)-6-methyl-2-pyrimidinyl]amino]cyclohexyl]-3,5-dimethoxy- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 771546-77-1 CAPLUS

CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-4-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 771546-79-3 CAPLUS

CN Benzamide, 3-bromo-4-chloro-N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 771549-06-5 CAPLUS

Serial No.: 10/812,075

CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5,6-dimethyl-2-pyrimidinyl]amino]cyclohexyl]-3-methoxy- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 771549-30-5 CAPLUS

CN Benzamide, 3-cyano-N-[cis-4-[[4-(dimethylamino)-5,6-dimethyl-2-pyrimidinyl]amino]cyclohexyl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 771549-32-7 CAPLUS

CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5,6-dimethyl-2-pyrimidinyl]amino]cyclohexyl]-3-methyl- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 771549-34-9 CAPLUS

CN Benzamide, 3-chloro-N-[cis-4-[[4-(dimethylamino)-5,6-dimethyl-2-pyrimidinyl]amino]cyclohexyl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 771549-36-1 CAPLUS

CN Benzamide, 3-bromo-N-[cis-4-[[4-(dimethylamino)-5,6-dimethyl-2-pyrimidinyl]amino]cyclohexyl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 771549-38-3 CAPLUS

CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5,6-dimethyl-2-pyrimidinyl]amino]cyclohexyl]-3,5-dimethoxy- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 771549-40-7 CAPLUS

CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5,6-dimethyl-2-pyrimidinyl]amino]cyclohexyl]-3,5-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 771549-42-9 CAPLUS

CN Benzamide, 3,4-dichloro-N-[cis-4-[[4-(dimethylamino)-5,6-dimethyl-2-pyrimidinyl]amino]cyclohexyl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 771549-44-1 CAPLUS

CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5,6-dimethyl-2-pyrimidinyl]amino]cyclohexyl]-4-(trifluoromethoxy)- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 771549-46-3 CAPLUS

CN Benzamide, 4-cyano-N-[cis-4-[[4-(dimethylamino)-5,6-dimethyl-2-pyrimidinyl]amino]cyclohexyl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 771549-48-5 CAPLUS

CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5,6-dimethyl-2-pyrimidinyl]amino]cyclohexyl]-4-methyl- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 771549-50-9 CAPLUS

CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5,6-dimethyl-2-pyrimidinyl]amino]cyclohexyl]-4-fluoro- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 771549-52-1 CAPLUS

CN Benzamide, 4-chloro-N-[cis-4-[[4-(dimethylamino)-5,6-dimethyl-2-pyrimidinyl]amino]cyclohexyl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 771549-54-3 CAPLUS

CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5,6-dimethyl-2-pyrimidinyl]amino]cyclohexyl]-2-methoxy- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 771549-56-5 CAPLUS

CN Benzamide, 4-bromo-N-[cis-4-[[4-(dimethylamino)-5,6-dimethyl-2-pyrimidinyl]amino]cyclohexyl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 771549-58-7 CAPLUS

CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5,6-dimethyl-2-pyrimidinyl]amino]cyclohexyl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 771549-60-1 CAPLUS

CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5,6-dimethyl-2-pyrimidinyl]amino]cyclohexyl]-4-ethoxy- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 771549-62-3 CAPLUS

CN Benzamide, 4-bromo-N-[cis-4-[[4-(dimethylamino)-5,6-dimethyl-2-pyrimidinyl]amino]cyclohexyl]-3-methyl- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 771549-64-5 CAPLUS

CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5,6-dimethyl-2-pyrimidinyl]amino]cyclohexyl]-3-fluoro-4-methyl- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 771549-66-7 CAPLUS

CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5,6-dimethyl-2-pyrimidinyl]amino]cyclohexyl]-4-fluoro-3-methyl- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 771549-68-9 CAPLUS

CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5,6-dimethyl-2-pyrimidinyl]amino]cyclohexyl]-3-ethyl- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 771549-70-3 CAPLUS

CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5,6-dimethyl-2-pyrimidinyl]amino]cyclohexyl]-3-(trifluoromethoxy)- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 771549-78-1 CAPLUS

CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5,6-dimethyl-2-pyrimidinyl]amino]cyclohexyl]-3,5-diethoxy- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 771549-80-5 CAPLUS

CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5,6-dimethyl-2-pyrimidinyl]amino]cyclohexyl]-3-ethoxy- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 771549-82-7 CAPLUS

CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5,6-dimethyl-2-pyrimidinyl]amino]cyclohexyl]-3-(1-methylethoxy)- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 771549-86-1 CAPLUS

CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5,6-dimethyl-2-pyrimidinyl]amino]cyclohexyl]-3,4-difluoro- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 771550-50-6 CAPLUS

CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 771550-52-8 CAPLUS

CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-3-fluoro- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 771550-54-0 CAPLUS

CN Benzamide, 3-bromo-N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 771550-56-2 CAPLUS

CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-4-fluoro- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 771550-58-4 CAPLUS

CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-3,5-dimethoxy- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 771550-60-8 CAPLUS

CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-2,4-difluoro- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771550-62-0 CAPLUS


CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-2,5-difluoro- (9CI) (CA INDEX NAME)

Relative stereochemistry.

RN 771550-64-2 CAPLUS

CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-2,3,4-trifluoro- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 771550-66-4 CAPLUS

CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 771550-68-6 CAPLUS

CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-4-(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 771550-70-0 CAPLUS

CN Benzamide, 4-butyl-N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 771550-72-2 CAPLUS

CN Benzamide, 4-chloro-N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 771550-74-4 CAPLUS

CN Benzamide, 3-cyano-N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.




Serial No.: 10/812,075

RN 771550-76-6 CAPLUS

CN Benzamide, 4-cyano-N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 771550-78-8 CAPLUS

CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-2-methoxy- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 771550-80-2 CAPLUS

CN Benzamide, 4-bromo-N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 771550-82-4 CAPLUS

CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 771550-84-6 CAPLUS

CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-4-methoxy- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 771550-86-8 CAPLUS

CN Benzamide, 2-bromo-N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 771550-88-0 CAPLUS

CN Benzamide, 2-chloro-N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 771550-90-4 CAPLUS

CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-2-fluoro- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 771550-92-6 CAPLUS

CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-2-methyl- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 771550-94-8 CAPLUS

CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-2-(trifluoromethyl)- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 771550-96-0 CAPLUS

CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-4-fluoro-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 771550-98-2 CAPLUS

CN Benzamide, 4-bromo-N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-3-methyl- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 771551-00-9 CAPLUS

CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-4-ethoxy- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 771551-02-1 CAPLUS

CN Benzamide, 3-(dimethylamino)-N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 771551-04-3 CAPLUS

CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-4-fluoro-3-methyl- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 771551-06-5 CAPLUS

CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-3-fluoro-4-methyl- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 771551-08-7 CAPLUS

CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-3-ethyl- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 771551-12-3 CAPLUS

CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-3-ethoxy- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 771551-14-5 CAPLUS

CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-3-(1-methylethoxy)- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 771551-16-7 CAPLUS

CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-3,5-diethoxy- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 771551-18-9 CAPLUS

CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-3-fluoro-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 771551-20-3 CAPLUS

CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-3-fluoro-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 771551-22-5 CAPLUS

CN Benzamide, 3-chloro-N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-4-fluoro- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 771551-24-7 CAPLUS

CN Benzamide, 3,5-dibromo-N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 771551-26-9 CAPLUS

CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-3,5-dimethyl- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 771551-28-1 CAPLUS

CN Benzamide, 4-chloro-N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-3-methyl- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 771551-30-5 CAPLUS

CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-4-methoxy-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 771551-32-7 CAPLUS

CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-4-methyl- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 771551-34-9 CAPLUS

CN Benzamide, 3-chloro-N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 771551-56-5 CAPLUS

CN Benzamide, N-[cis-4-[[4-(dimethylamino)-6-methyl-2-pyrimidinyl]amino]cyclohexyl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 771551-58-7 CAPLUS

CN Benzamide, 4-butyl-N-[cis-4-[[4-(dimethylamino)-6-methyl-2-pyrimidinyl]amino]cyclohexyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 771551-60-1 CAPLUS

Serial No.: 10/812,075

CN Benzamide, N-[cis-4-[[4-(dimethylamino)-6-methyl-2-pyrimidinyl]amino]cyclohexyl]-3-fluoro- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 771551-62-3 CAPLUS

CN Benzamide, N-[cis-4-[[4-(dimethylamino)-6-methyl-2-pyrimidinyl]amino]cyclohexyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 771551-64-5 CAPLUS

CN Benzamide, N-[cis-4-[[4-(dimethylamino)-6-methyl-2-pyrimidinyl]amino]cyclohexyl]-2-methoxy- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 771551-66-7 . CAPLUS

CN Benzamide, N-[cis-4-[[4-(dimethylamino)-6-methyl-2-pyrimidinyl]amino]cyclohexyl]-4-methoxy- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 771551-68-9 CAPLUS

CN Benzamide, 3-cyano-N-[cis-4-[[4-(dimethylamino)-6-methyl-2-pyrimidinyl]amino]cyclohexyl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 771551-70-3 CAPLUS

CN Benzamide, 4-cyano-N-[cis-4-[[4-(dimethylamino)-6-methyl-2-pyrimidinyl]amino]cyclohexyl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 771551-72-5 CAPLUS


CN Benzamide, N-[cis-4-[[4-(dimethylamino)-6-methyl-2-pyrimidinyl]amino]cyclohexyl]-3-fluoro-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 771551-74-7 CAPLUS
 CN Benzamide, N-[cis-4-[[4-(dimethylamino)-6-methyl-2-pyrimidinyl]amino]cyclohexyl]-4-fluoro-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 771551-76-9 CAPLUS
 CN Benzamide, N-[cis-4-[[4-(dimethylamino)-6-methyl-2-pyrimidinyl]amino]cyclohexyl]-3-fluoro-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 771551-78-1 CAPLUS
 CN Benzamide, 3-chloro-N-[cis-4-[[4-(dimethylamino)-6-methyl-2-pyrimidinyl]amino]cyclohexyl]-4-fluoro- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771551-80-5 CAPLUS
 CN Benzamide, N-[cis-4-[[4-(dimethylamino)-6-methyl-2-pyrimidinyl]amino]cyclohexyl]-4-fluoro-3-methyl- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 771551-82-7 CAPLUS

CN Benzamide, N-[cis-4-[[4-(dimethylamino)-6-methyl-2-pyrimidinyl]amino]cyclohexyl]-3-fluoro-4-methyl- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 771551-84-9 CAPLUS

CN Benzamide, 3,5-dichloro-N-[cis-4-[[4-(dimethylamino)-6-methyl-2-pyrimidinyl]amino]cyclohexyl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 771551-86-1 CAPLUS

CN Benzamide, N-[cis-4-[[4-(dimethylamino)-6-methyl-2-pyrimidinyl]amino]cyclohexyl]-3-(trifluoromethoxy)- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 771551-88-3 CAPLUS

CN Benzamide, N-[cis-4-[[4-(dimethylamino)-6-methyl-2-pyrimidinyl]amino]cyclohexyl]-3,5-difluoro- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 771551-90-7 CAPLUS

CN Benzamide, 4-bromo-N-[cis-4-[[4-(dimethylamino)-6-methyl-2-pyrimidinyl]amino]cyclohexyl]-3-methyl- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 771551-92-9 CAPLUS

CN Benzamide, N-[cis-4-[[4-(dimethylamino)-6-methyl-2-pyrimidinyl]amino]cyclohexyl]-3-ethyl- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 771551-94-1 CAPLUS

CN Benzamide, N-[cis-4-[[4-(dimethylamino)-6-methyl-2-pyrimidinyl]amino]cyclohexyl]-4-ethoxy- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 771551-96-3 CAPLUS

CN Benzamide, N-[cis-4-[[4-(dimethylamino)-6-methyl-2-pyrimidinyl]amino]cyclohexyl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 771551-98-5 CAPLUS

CN Benzamide, 4-bromo-N-[cis-4-[[4-(dimethylamino)-6-methyl-2-pyrimidinyl]amino]cyclohexyl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 771552-00-2 CAPLUS

CN Benzamide, N-[cis-4-[[4-(dimethylamino)-6-methyl-2-pyrimidinyl]amino]cyclohexyl]-4-ethyl- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 771552-02-4 CAPLUS

CN Benzamide, N-[cis-4-[[4-(dimethylamino)-6-methyl-2-pyrimidinyl]amino]cyclohexyl]-3,5-diethoxy- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 771552-04-6 CAPLUS

CN Benzamide, N-[cis-4-[[4-(dimethylamino)-6-methyl-2-pyrimidinyl]amino]cyclohexyl]-3-ethoxy- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 771552-06-8 CAPLUS

CN Benzamide, N-[cis-4-[[4-(dimethylamino)-6-methyl-2-pyrimidinyl]amino]cyclohexyl]-3-(1-methylethoxy)- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 771552-14-8 CAPLUS

CN Benzamide, N-[cis-4-[[4-(dimethylamino)-6-methyl-2-pyrimidinyl]amino]cyclohexyl]-4-methoxy-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 771552-16-0 CAPLUS

CN Benzamide, 4-chloro-N-[cis-4-[[4-(dimethylamino)-6-methyl-2-pyrimidinyl]amino]cyclohexyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 771552-18-2 CAPLUS

CN Benzamide, N-[cis-4-[[4-(dimethylamino)-6-methyl-2-pyrimidinyl]amino]cyclohexyl]-3-methyl- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 771552-20-6 CAPLUS


CN Benzamide, N-[cis-4-[[4-(dimethylamino)-6-methyl-2-pyrimidinyl]amino]cyclohexyl]-3,4,5-trimethoxy- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771552-22-8 CAPLUS


CN Benzamide, N-[4-[[4-(dimethylamino)-6-methyl-2-pyrimidinyl]amino]cyclohexyl]-3-nitro- (9CI) (CA INDEX NAME)



RN 771552-26-2 CAPLUS

CN Benzamide, 3,4-dichloro-N-[cis-4-[[4-(dimethylamino)-6-methyl-2-pyrimidinyl]amino]cyclohexyl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 771553-00-5 CAPLUS

CN Benzamide, 3,4-dichloro-N-[cis-4-[[5-methyl-4-(methylamino)-2-pyrimidinyl]amino]cyclohexyl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 771555-36-3 CAPLUS

CN Benzamide, N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-3-methoxy-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 771555-45-4 CAPLUS

CN Benzamide, 3-chloro-N-[cis-4-[[4-(dimethylamino)-6-methyl-2-pyrimidinyl]amino]cyclohexyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 771556-86-6 CAPLUS

CN Benzamide, 3-chloro-N-[cis-4-[[4-(dimethylamino)-5-methyl-2-pyrimidinyl]amino]cyclohexyl]-4-fluoro-, monohydrochloride (9CI) (CA INDEX NAME)


Relative stereochemistry.



● HCl


RN 771556-89-9 CAPLUS
 CN Benzamide, 3-chloro-N-[cis-4-[[4-(dimethylamino)-6-methyl-2-pyrimidinyl]amino]cyclohexyl]-4-fluoro-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 771556-90-2 CAPLUS
 CN Benzamide, N-[cis-4-[[4-(dimethylamino)-6-ethyl-2-pyrimidinyl]amino]cyclohexyl]-3,4-difluoro-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 771557-07-4 CAPLUS
 CN Benzamide, N-[cis-4-[(4-amino-5-methyl-2-pyrimidinyl)amino]cyclohexyl]-3,5-bis(trifluoromethyl)-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 771557-21-2 CAPLUS

CN Benzamide, N-[cis-4-[[4-methyl-6-(methylamino)-2-pyrimidinyl]amino]cyclohexyl]-4-(trifluoromethoxy)-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl


Serial No.: 10/812,075

Structure Search

=> D QUE L14

L8

STR



Structure attributes must be viewed using STN Express query preparation.

L13 278 SEA FILE=REGISTRY SSS FUL L8

L14 3 SEA FILE=CAPLUS ABB=ON PLU=ON L13

=> S L14 NOT L25

L28 0 L14 NOT L25

=> FILE MARPAT

FILE 'MARPAT' ENTERED AT 10:40:40 ON 05 JUN 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 American Chemical Society (ACS)

FILE CONTENT: 1961-PRESENT VOL 146 ISS 23 (20070601/ED)

SOME MARPAT RECORDS ARE DERIVED FROM INPI DATA FOR 1961-1987

MOST RECENT CITATIONS FOR PATENTS FROM MAJOR ISSUING AGENCIES
(COVERAGE TO THESE DATES IS NOT COMPLETE):


| | | |
|----|--------------|-------------|
| US | 2007088073 | 19 APR 2007 |
| DE | 102006048036 | 12 APR 2007 |
| EP | 1774957 | 18 APR 2007 |
| JP | 2007103208 | 19 APR 2007 |
| WO | 2007047881 | 26 APR 2007 |
| GB | 2430675 | 04 APR 2007 |
| FR | 2891841 | 13 APR 2007 |
| RU | 2296767 | 10 APR 2007 |
| CA | 2522632 | 06 APR 2007 |

Expanded G-group definition display now available.

=> D QUE L27

L8

STR



Structure attributes must be viewed using STN Express query preparation.
 L27 24 SEA FILE=MARPAT SSS FUL L8

=> S L27 NOT L25
 1 L25
 L29 24 L27 NOT L25

=> D IBIB AB QHIT L29 1-24

L29 ANSWER 1 OF 24 MARPAT COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 146:45539 MARPAT Full-text
 TITLE: Preparation of aminopyridine derivatives as selective
 Aurora-A inhibitors for treatment of cancer
 INVENTOR(S): Kato, Tetsuya; Kawanishi, Nobuhiko; Mita, Takashi;
 Ohkubo, Mitsuru; Shimomura, Toshiyasu
 PATENT ASSIGNEE(S): Banyu Pharmaceutical Co., Ltd., Japan
 SOURCE: PCT Int. Appl., 151pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 3
 PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|------------------|----------|
| WO 2006129842 | A1 | 20061207 | WO 2006-JP311179 | 20060530 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |

WO 2006046734 A2 20060504 WO 2005-JP19957 20051025

WO 2006046734 A3 20060921

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

US 2006106029 A1 20060518

US 2005-258447 20051025

PRIORITY APPLN. INFO.:

JP 2005-161156 20050601

WO 2005-JP19957 20051025

JP 2004-315152 20041029


US 2005-692537P 20050621

AB The title compds. I [A1 is (RbjCRbj')m2; A2 is (RaiCRai')m1; A3 is (Y2Rc)n1CO(Y3Rd)n2R; m1 and m2 each is 1, 2, or 3; n1 and n2 each is 0 or 1; i is an integer of 1 to m1; j is an integer of 1 to m2; R is optionally substituted aryl, heteroaryl, or cycloalkyl; Rai and Rai' each is hydrogen, alkyl; Rbj and Rbj' each is hydrogen, alkyl; Rc, Rd, and R1 each is hydrogen, alkyl; X1 is CH, CX1a, N; X1a is (un)substituted alkyl; X2 is CH, N, etc.; X3 is CH, CX3a, N; X3a is (un)substituted alkyl; X4 is CH or N; Y1, Y2, and Y3 are the same or different and each is CH or N; Z1 and Z2 are the same or different and each is CH or N; and W is a 5-membered aromatic heterocycle, e.g., pyrazole or thiazole] are prepared. Thus, (5-bromothiazol-2-yl)-(6-(4-benzoylpiperazin-1-ylmethyl)pyridin-2-yl)amine was prepared in a multistep process from 2-aminothiazole and 2,6-dichloropyridine. Compds. of this invention showed IC50 values of 0.36 nM to 110 nM against Aurora-A; they showed IC50 values of 47 nM to 28000 nM against Aurora-B.

MSTR 1

G14-NH-G26-G10-TG1-TG5-TG9

G1 = 11-9 13-15



G2 = CH

G3 = (1-3) 17



G5 = 20-10 21-16

$2\text{G}^6 \rightarrow 2\text{I}^{(0)}$


G6 = NH
 G9 = Ph (opt. substd. by 1 or more G23)
 G10 = NH
 G11 = N / 31

$3\text{I} \text{---} \text{G}^{12}$

G12 = alkyl <containing 1-6 C> (opt. substd.)
 G13 = N / 84

$8\text{I} \text{---} \text{G}^{30}$

G26 = 2-7 4-9



Patent location: disclosure
 Note: substitution is restricted
 Note: or pharmaceutically acceptable salts or esters
 Note: additional oxo formation also disclosed

REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT

L29 ANSWER 2 OF 24 MARPAT COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 146:20277 MARPAT Full-text
 TITLE: Method for treating B cell regulated autoimmune disorders
 INVENTOR(S): Foley, Kevin; Bertin, John; Grant, Ethan P.
 PATENT ASSIGNEE(S): Synta Pharmaceuticals Corp., USA
 SOURCE: PCT Int. Appl., 327pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------------|------|-------|-----------------|-------|
| ----- | ---- | ----- | ----- | ----- |

Serial No.: 10/812,075

WO 2006128172 A2 20061130 WO 2006-US20908 20060526

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM


US 2007032493 A1 20070208 US 2006-442744 20060526

PRIORITY APPLN. INFO.:

US 2005-685077P 20050526

AB The invention relates to a method for treating B-cell regulated autoimmune disorders using compds. that modulate the activity of c-Rel. In the examples, it was shown that N-(3-methylbenzylidene)-N'[6-morpholin-4-yl-2-(2-pyridin-2-ylethoxy)-pyrimidin-4-yl]hydrazine inhibited the accumulation of c-Rel in the nucleus and its binding to DNA and enhanced the apoptosis of B cells.


MSTR 1




G1 = 7




G2 = N / 26



G3 = 308



G8 = NH
G13 = Me
G21 = NH
G22 = 1409



G70 = C(O)

Patent location:

claim 1

Note:

substitution is restricted

Note:

also incorporates claims 43, 83, and 191

Note:

additional substitution also claimed

Note:

or pharmaceutically acceptable salts, solvates, clathrates, hydrates, polymorphs, or prodrugs

L29 ANSWER 3 OF 24 MARPAT COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 146:20264 MARPAT Full-text

TITLE: Method for treating cancer

INVENTOR(S): Bertin, John; Grant, Ethan P.

PATENT ASSIGNEE(S): Synta Pharmaceuticals Corp., USA

SOURCE: PCT Int. Appl., 354pp.

CODEN: PIXXD2

DOCUMENT TYPE:

Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:


| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|-----------------|----------|
| ----- | ---- | ----- | ----- | ----- |
| WO 2006128129 | A2 | 20061130 | WO 2006-US20821 | 20060526 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |

PRIORITY APPLN. INFO.:

US 2005-685056P 20050526

US 2005-720357P 20050923

AB The invention relates to a method for treating cancers using compds. that modulate the activity of c-Rel.

MSTR 1

G1 = 7

~~G8~~—~~G6~~

G2 = N / 26

~~G6~~—G13

G3 = 308

~~G6~~¹—~~G6~~²

G8 = NH
G13 = Me
G21 = NH
G22 = 1409

~~P1409~~—C₆H₄—NH—G70—p—C₆H₄—G71

G70 = C(O)
Patent location: claim 1
Note: substitution is restricted
Note: also incorporates claims 41, 81, and 189
Note: additional substitution also claimed
Note: or pharmaceutically acceptable salts, solvates, clathrates, hydrates, polymorphs, or prodrugs

L29 ANSWER 4 OF 24 MARPAT COPYRIGHT 2007 ACS on STN
(ALL HITS ARE ITERATION INCOMPLETES)

ACCESSION NUMBER: 145:167276 MARPAT Full-text
TITLE: Preparation of triazolopyrimidine derivatives as serine-tyrosine and tyrosine kinases inhibitors
INVENTOR(S): Ludovici, Donald W.; Connors, Richard W.; Coats, Steven J.; Liu, Li; De Corte, Bart L.; Johnson, Dana L.; Schulz, Mark J.
PATENT ASSIGNEE(S): Janssen Pharmaceutica N.V., Belg.
SOURCE: PCT Int. Appl., 97 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|--|------|----------|-----------------|----------|
| WO 2006076442 | A2 | 20060720 | WO 2006-US999 | 20060111 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, | | | | |

CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM


US 2007015207 A1 20070118 US 2006-329642 20060111

PRIORITY APPLN. INFO.:

US 2005-644466P 20050114



AB Title compds. represented by the formula I [wherein R1 = (un)substituted alkyl, alkenyl, alkynyl, etc.; R2 = H, (cyclo)alkyl, hydroxy, amino, etc.; R3 = aryl(alkyl), cycloalkyl, quinolinyl, etc.; and pharmaceutically acceptable salts thereof] were prepared as serine-tyrosine and tyrosine kinases inhibitors. For example, II was provided in a multi-step synthesis starting from reaction of 3-dimethylamino-1-propanol with 1-fluoro-4-nitrobenzene. I were tested for effects on the tyrosine kinase activity of Focal Adhesion Kinase (FAK) in vitro FAK ELISA kinase assay and CAK (Cyclin Dependent Kinase Activating Kinase) assay.

MSTR 1 ITERATION INCOMPLETE



G1 = 12 / carbocycle <containing 7-11 C, aromatic, 6 normalized bonds, bicyclic, (0-1) 3-membered, (0-1) 4-membered, (0-1) 5-membered, (1-2) 6-membered, (0-1) 7-membered rings only> / heterocycle <containing 3-11 atoms, 1 or more heteroatoms, zero or more N, zero or more O, zero or more S (no other heteroatoms), aromatic, 6 or more normalized bonds, bicyclic, (0-1) 3-membered, (0-1) 4-membered, (0-1) 5-membered, (1-2) 6-membered, (0-1) 7-membered rings only> / (Specifically claimed: 231 / 286)














¹G2—G4













G2 = phenylene (opt. substd. by G3)
 G3 = alkyl <containing 1-6 C> / alkoxy <containing 1-6 C> / cycloalkyl <containing 3-7 C> / OH / NH2 / alkylamino <containing 1-6 C> / dialkylamino <each alkyl containing 1-6 C> /




(Specifically claimed: OMe)

G4 = alkyl <containing 1-8 C>
 (opt. substd. by (1-3) G5) / alkenyl <containing 2-8 C>
 (opt. substd. by G14) / alkynyl <containing 2-8 C>
 (opt. substd. by G14) / alkoxy <containing 1-8 C>
 (opt. substd. by (1-3) G15) / 31 /
 alkoxycarbonyl <containing 1-6 C>
 (opt. substd. by (1-3) G15) / CONH2 /
 alkylaminocarbonyl <containing 1-6 C> /
 dialkylaminocarbonyl <each alkyl containing 1-6 C> / aryl /
 tetrazolyl (opt. substd. by (1-3) alkyl <containing 1-6 C>) /
 thiadiazolyl (opt. substd. by (1-3) alkyl <containing 1-6 C>
) / oxazolyl (opt. substd. by (1-3) alkyl <containing 1-6 C>
) / pyrimidinyl (opt. substd. by (1-3)
 alkyl <containing 1-6 C>) / 37 / (Specifically claimed: 185 /
 201 / 200 / 211 / 224 / 241 / Ph / 242 / 247 / 253 / 257 /
 CONHMe / 269 / OMe / 272 / 289 / 299 / 305 / 317 / 318 /
 336 / 350 / 360 / 361 / 370 / 379)

 ${}_{31}C(O).G16$ ${}_{37}G17-G18$ 



G5 = NH₂ / 14 / heterocycle <containing 1-4 heteroatoms, 1 or more N, zero or more O, zero or more S (no other heteroatoms), attached through 1 or more N, monocyclic> (opt. substd. by (1-3) G11) / 20 / 23 / alkoxy-carbonyl <containing 1-6 C>



G6 = NH / 16



G7 = alkyl <containing 1-6 C> (opt. substd. by (1-3) G8) / cycloalkyl <containing 3-7 C> (opt. substd. by (1-3) G8)
G8 = NH₂ / alkylamino <containing 1-6 C> /

dialkylamino <each alkyl containing 1-6 C> /
heterocycle <containing 5-8 atoms, 1 or more heteroatoms,
1 or more N, zero or more O, zero or more S (no other
heteroatoms), attached through 1 or more N,
5- to 8-membered monocyclic ring>
(opt. substd. by (1-3) G9) / 18 / OH /
alkoxycarbonyl <containing 1-6 C> / CO₂H / aryl /
heterocycle <containing 5-6 atoms, 1-3 heteroatoms, 1-2 N,
0-1 O, 0-1 S (no other heteroatoms), aromatic,
2 or more double bonds, 5- to 6-membered monocyclic ring>
(opt. substd. by (1-3) alkyl <containing 1-6 C>)

₁G¹⁰=O

- G9 = alkyl <containing 1-6 C> /
alkoxy <containing 1-6 C> / alkyl <containing 1-6 C>
(substd. by 1 or more aryl) / alkoxycarbonyl <containing 1-6
C> / CO₂H / OH
- G10 = heterocycle <containing 5-8 atoms,
1 or more heteroatoms, 1 or more N, zero or more O,
zero or more S (no other heteroatoms),
attached through 1 or more N, 5- to 8-membered monocyclic
ring> (opt. substd. by (1-3) G9)
- G11 = alkyl <containing 1-6 C>
(opt. substd. by 1 or more aryl) /
alkoxycarbonyl <containing 1-6 C> / CO₂H / OH
- G12 = heterocycle <containing 1-4 heteroatoms,
1 or more N, zero or more O, zero or more S (no other
heteroatoms), attached through 1 or more N, monocyclic>
(opt. substd. by (1-3) G11)
- G13 = alkyl <containing 1-6 C>
- G14 = aryl / alkoxycarbonyl <containing 1-6 C>
- G15 = NH₂ / 27 / heterocycle <containing 1-4 heteroatoms,
1 or more N, zero or more O, zero or more S (no other
heteroatoms), attached through 1 or more N, monocyclic>
(opt. substd. by (1-3) G11) / 29 / OH

- G16 = NH₂ / 33 / heterocycle <containing 1-4 heteroatoms,
1 or more N, zero or more O, zero or more S (no other
heteroatoms), attached through 1 or more N, monocyclic>
(opt. substd. by (1-3) G11) / 35 / OH












₃G⁶—G⁷ ₃G¹²=O




- G17 = S(O) / SO₂
- G18 = NH₂ / dialkylamino <containing 1-6 C> /
dialkylamino <each alkyl containing 1-6 C> /
heterocycle <containing 5-8 atoms, 1 or more heteroatoms,
1 or more N, zero or more O, zero or more S (no other
heteroatoms), attached through 1 or more N,

5- to 8-membered monocyclic ring>
(opt. substd. by (1-3) G9) / 39

$\text{g}^{10=0}$

G19 = alkyl <containing 1-6 C> (substd. by G20) /
aryl (opt. substd. by (1-3) G21) /
cycloalkyl <containing 3-7 C> (opt. substd. by (1-3) G22) /
carbocycle <containing 7-11 C, aromatic, 6 normalized bonds,
bicyclic, (0-1) 3-membered, (0-1) 4-membered,
(0-1) 5-membered, (1-2) 6-membered,
(0-1) 7-membered rings only> (opt. substd. by 1 or more G24)
/ quinolinyl (opt. substd.) / benzothiazolyl (opt. substd.) /
benzimidazolyl (opt. substd.) / pyrazolyl (opt. substd.) /
72 / 94 / 116 / 144 / 168 / (Specifically claimed: 400 /
Ph (opt. substd. by 1 or more G28) / cyclohexyl /
2-naphthyl / cyclohexyl / 408 / 438 / 447 / 454 / 474 /
CH2Ph / 494 / 504 / cyclopentyl / 516 / 530)





- G20 = aryl (opt. substd. by (1-3) G21)
 G21 = alkyl <containing 1-6 C> /
 alkenyl <containing 2-6 C> / alkynyl <containing 2-6 C> /
 alkoxy <containing 1-6 C> / OH / CN / F / CO2H /
 cycloalkyl <containing 3-7 C> / NH2 / 42 /
 heterocycle <containing 1-4 heteroatoms, 1 or more N,
 zero or more O, zero or more S (no other heteroatoms),
 attached through 1 or more N, monocyclic>
 (opt. substd. by (1-3) G11) / 44 / 46 /
 alkoxycarbonyl <containing 1-6 C> / 48 / pyrimidinyl /
 thiadiazolyl / tetrazolyl / pyrazolyl / oxazolyl



- G22 = OH / NH2 / 50 / heterocycle <containing 1-4
 heteroatoms, 1 or more N, zero or more O,
 zero or more S (no other heteroatoms),
 attached through 1 or more N, monocyclic>
 (opt. substd. by (1-3) G11) / 52 / 54 /
 alkoxycarbonyl <containing 1-6 C> / CO2H / 56



- G23 = NH2 / alkylamino <containing 1-6 C> /
 dialkylamino <each alkyl containing 1-6 C> /
 heterocycle <containing 5-8 atoms, 1 or more heteroatoms,
 1 or more N, zero or more O, zero or more S (no other
 heteroatoms), attached through 1 or more N,
 5- to 8-membered monocyclic ring>
 (opt. substd. by (1-3) G9) / 58 / alkyl <containing 1-6 C>



- G24 = alkyl <containing 1-6 C> /
 alkenyl <containing 2-6 C> / alkynyl <containing 2-6 C> /
 alkoxy <containing 1-6 C> / OH / CN / F / CO2H /
 cycloalkyl <containing 3-7 C> / NH2 / 66 /
 heterocycle <containing 1-4 heteroatoms, 1 or more N,

Serial No.: 10/812,075


zero or more O, zero or more S (no other heteroatoms),
attached through 1 or more N, monocyclic>
(opt. substd. by (1-3) G11) / 60 / 62 /
alkoxycarbonyl <containing 1-6 C> / 68 / pyrimidinyl /
thiadiazolyl / tetrazolyl / pyrazolyl / oxazolyl




G25 = H / R
G26 = pyrrolidino / 324 / 339 / 344





G27 = OH / morpholino / pyrrolidino / 389



G28 = Me / OMe / F / CN
G29 = cyclohexyl / morpholino / 417 / 467 / 485



G30 = 426 / 455 / 465 / CONHMe / SO2NH2 / 489 / 532



Patent location:
Note:

claim 21
or pharmaceutically acceptable salts

L29 ANSWER 5 OF 24 MARPAT COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 144:450735 MARPAT Full-text
 TITLE: Preparation of novel aminopyridine derivatives having selective Aurora-A protein kinase inhibitory effect
 INVENTOR(S): Ohkubo, Mitsuru; Kato, Tetsuya; Kawanishi, Nobuhiko; Mita, Takashi; Shimomura, Toshiyasu
 PATENT ASSIGNEE(S): Banyu Pharmaceutical Co., Ltd., Japan
 SOURCE: PCT Int. Appl., 148 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 3
 PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------------------------|--|----------|------------------|----------|
| ----- | --- | ----- | ----- | ----- |
| WO 2006046734 | A2 | 20060504 | WO 2005-JP19957 | 20051025 |
| WO 2006046734 | A3 | 20060921 | | |
| W: | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | |
| RW: | AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | |
| US 2006106029 | A1 | 20060518 | US 2005-258447 | 20051025 |
| WO 2006129842 | A1 | 20061207 | WO 2006-JP311179 | 20060530 |
| W: | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | |
| RW: | AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | |
| PRIORITY APPLN. INFO.: | | | JP 2004-315152 | 20041029 |
| | | | JP 2005-161156 | 20050601 |
| | | | US 2005-692537P | 20050621 |
| | | | WO 2005-JP19957 | 20051025 |


AB The title compds. (I) or pharmaceutically acceptable salts or ester thereof [wherein m1, m2 = 1, 2, 3; n1, n2 = 0, 1; i = an integer of from 1 to m1; j = an integer of from 1 to m2; R = (un)substituted aryl, heteroaryl or cycloalkyl; Rai, Rai', Rbj, Rbj', Rc, Rd, Re = H, lower alkyl; X1 = CH, CX1a, N; wherein X1a = (un)substituted lower alkyl; X2 = CH, N; X3 = CH, N, CX3a; wherein X3a = (un)substituted lower alkyl; X4 = CH, N; 1 or 2 of X1-X4 is N; Y1, Y2, Y3 = CH, N; Z1, Z2 = CH, N; W = a 5-membered aromatic heterocycle of formula Q including pyrazole or thiazole; wherein W1 = CH, N, NH, O, S; W2 = CH, CW2a, N, NW2b, O, S; wherein W2a, W2b = H, halo, cyano, C1-2 alkyl, C3-5 cycloalkyl, 1 or 2 halo-substituted C1-2 alkyl] are prepared These compds. are selective inhibitors of Aurora-A protein kinase over Aurora-B protein

kinase and exhibit synergistic anticancer activity in combination with other anticancer agents. An anticancer agent containing the compound I, and the combined use of the above anticancer agent with another anticancer agent are also disclosed. Thus, a mixture of 2.70 g 6-chloromethyl-N-(thiazol-2-yl)pyridin-2-amine, 4.00 g 1-(3-chloro-2-fluorobenzoyl)piperazine, and 6.25 mL N,N-diisopropylethylamine, and 30 mL DMF was stirred at 90° for 2 h to give, after workup and silica gel chromatog., 6-[(4-(3-chloro-2-fluorobenzoyl)piperazin-1-yl)methyl]-N-thiazol-2-ylpyridin-2-amine (II; R = H). II (R = H) and II (R = 2-methyl-2H-tetrazol-5-yl) showed IC₅₀ of 0.67 and 0.32 nM against Aurora-A protein kinase, resp., and 440 and 190 nM against Aurora-B protein kinase, resp. They showed IC₅₀ of 11.00 and 0.21 μM against human cervical cancer cell (HeLa S3), resp., and also showed synergistic antiproliferative activity against HeLa S3 cells in combination with paclitaxel.

MSTR 1

G14—NH—G26—G10—G1—G5—G9

G1 = 11-9 13-15



G2 = CH
G3 = (1-3) 17




G5 = 20-10 21-16

2G6—2F(0)

G6 = NH
G9 = Ph (opt. substd. by 1 or more G23)
G10 = NH
G11 = N / 31

3F—G12

G12 = alkyl <containing 1-6 C> (opt. substd.)
 G13 = N / CH
 G26 = 2-7 4-9



Patent location: claim 1
 Note: substitution is restricted
 Note: or pharmaceutically acceptable salts or esters
 Note: additional oxo formation also disclosed

L29 ANSWER 6 OF 24 MARPAT COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 144:226245 MARPAT Full-text

TITLE: N-Phenyl-2-pyrimidinamine derivatives for the treatment of immunodeficiency disease-causing viral infections

INVENTOR(S): Zeichner, Steven; Krishnan, Vyjayanthi

PATENT ASSIGNEE(S): ICES the Secretary, Department of Health and Human Serv Government of the United States, As Represented, USA

SOURCE: PCT Int. Appl., 94 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---------------|------|----------|-----------------|----------|
| WO 2006017353 | A2 | 20060216 | WO 2005-US24922 | 20050713 |
| WO 2006017353 | A3 | 20060330 | | |


W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM


PRIORITY APPLN. INFO.: US 2004-588015P 20040713

AB The invention discloses treatment of cells or humans carrying or infected with a virus capable of causing an immunodeficiency disease with particular compds., including N-phenyl-2-pyrimidinamine derivs. (Markush included), as well as medicaments comprising those compds. and uses thereof. Compds. of the invention include imatinib mesylate.


MSTR 1A



G1 = NH₂
 G5 = loweralkyl
 G6 = phenylene (opt. substd. by 1 or more G35)
 G7 = 188




G9 = NH
 G11 = O
 G13 = bond
 G14 = 199




G17 = phenylene (opt. substd. by 1 or more G18)
 G30 = NH
 Patent location: claim 1
 Note: or salts


MSTR 1B



G1 = NH₂
 G5 = loweralkyl
 G6 = 492-7 493-491 494-490



G7 = 188



G9 = NH
 G11 = O
 G13 = bond
 G14 = 199

$$\text{G17}-\text{G20}$$

G17 = phenylene (opt. substd. by 1 or more G18)
 G30 = NH
 Patent location: claim 1
 Note: or salts

L29 ANSWER 7 OF 24 MARPAT COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 143:153303 MARPAT Full-text
 TITLE: A preparation of quinoline derivatives, useful as
 intermediates of receptor tyrosine kinase inhibitors
 INVENTOR(S): Chew, Warren; Papamichelakis, Maria; Wang, Youchu
 PATENT ASSIGNEE(S): Can.
 SOURCE: U.S. Pat. Appl. Publ., 22 pp.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|-----------------|----------|
| US 2005159446 | A1 | 20050721 | US 2005-36408 | 20050114 |
| AU 2005206541 | A1 | 20050804 | AU 2005-206541 | 20050114 |
| CA 2553729 | A1 | 20050804 | CA 2005-2553729 | 20050114 |
| WO 2005070890 | A2 | 20050804 | WO 2005-US1384 | 20050114 |
| WO 2005070890 | A3 | 20051103 | | |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| EP 1711467 | A2 | 20061018 | EP 2005-711511 | 20050114 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, BA, HR, IS, YU | | | | |

Serial No.: 10/812,075

| | | | | |
|------------------------|---|----------|------------------|----------|
| CN 1930128 | A | 20070314 | CN 2005-80007748 | 20050114 |
| NO 2006003501 | A | 20060928 | NO 2006-3501 | 20060801 |
| IN 2006KN02266 | A | 20070525 | IN 2006-KN2266 | 20060809 |
| PRIORITY APPLN. INFO.: | | | US 2004-537329P | 20040116 |
| | | | WO 2005-US1384 | 20050114 |

OTHER SOURCE(S): CASREACT 143:153303

AB The invention relates to a preparation of quinoline derivs. of formula I [wherein: G, R1, and R4 are independently selected from H, halogen, alkyl, alk(en/yn)yl, or hydroxymethyl, etc.; R2 is a leaving group; R3 is a protecting group; A is O, S, NH, or N(alkyl), etc.], useful as intermediates of receptor tyrosine kinase inhibitors (no biol. data). For instance, quinoline derivative II was prepared via intramol. heterocyclization of (phenylamino)propenoic acid amide III in the presence of phosphorus oxychloride.


MSTR 5

~~123-134~~

G14 = 180

~~180-304~~

G15 = 209-129 213-304



G16 = N


G17 = alkyl <containing 1-6 C> (opt. substd. by OH) /
N3 / 296

~~296~~—G24—Ph

G18 = 181

~~181-231~~

G21 = 265



G24 = C(O)

G28 = NH

Patent location: claim 20

Note: or salts

Note: substitution is restricted

L29 ANSWER 8 OF 24 MARPAT COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 143:115450 MARPAT Full-text

TITLE: Preparation of phosphodiesterase 4 inhibitors, including N-substituted diarylamine analogs, useful as cognition enhancers

INVENTOR(S): Schumacher, Richard; Hopper, Allen; Dunn, Robert; Kuester, Erik; Tehim, Ashok; Renau, Thomas E.; Caroon, Joan; Talamas, Francisco; Labadie, Sharada

PATENT ASSIGNEE(S): Memory Pharmaceuticals Corporation, USA

SOURCE: PCT Int. Appl., 136 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1


PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|------------------|--------------------------|
| WO 2005061458 | A2 | 20050707 | WO 2004-US41068 | 20041210 |
| WO 2005061458 | A3 | 20051013 | | |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| AU 2004303855 | A1 | 20050707 | AU 2004-303855 | 20041210 |
| CA 2548824 | A1 | 20050707 | CA 2004-2548824 | 20041210 |
| US 2005222207 | A1 | 20051006 | US 2004-8775 | 20041210 |
| EP 1692109 | A2 | 20060823 | EP 2004-813392 | 20041210 |
| R: AT, BE, CH, LI, LV, MK, CY, AL, BG, CZ, HR | | | | |
| BR 2004017110 | A | 20070206 | BR 2004-17110 | 20041210 |
| CN 1922144 | A | 20070228 | CN 2004-80041276 | 20041210 |
| JP 2007513957 | T | 20070531 | JP 2006-543943 | 20041210 |
| PRIORITY APPLN. INFO.: | | | | |
| | | | | US 2003-528486P 20031211 |
| | | | | WO 2004-US41068 20041210 |


AB PDE4 inhibition (no data) is achieved by novel compds., e.g., N-substituted diarylamine analogs (shown as I; variables defined below; e.g. 3-[N-[6-(cyclopropylmethoxy)-5-methoxypyridin-2-yl]-N-[(pyridin-3-

yl)methyl]amino]benzoic acid (shown as II)). For I: A, B and D are each N or CR5; R1 is halogen, alkyl having 1-4 C atoms, halogenated alkyl having 1-4 C atoms, OR6, COR6, CONR6, or NR6COR10; R2 is halogen, alkyl having 1-4 C atoms, halogenated alkyl having 1-4 C atoms, OR7, COR6, CONR6, or NR6COR10; R3 is C1-8 (un)substituted (un)branched alkyl, a partially unsatd. C5-14 carbocycle-alkyl, C7-19 arylalkyl or heteroarylalkyl group; R4 is C3-10 cycloalkyl, C6-14 aryl, heteroaryl having 5-10 ring atoms, a heterocyclic group, a heterocyclealkyl group; addnl. details including provisos are given in the claims. Although the methods of preparation are not claimed, .apprx.15 example preps. of I and intermediates are included. For example, N-(3-chlorophenyl)-N-[5-methoxy-6-(((3R)-tetrahydrofuran-3-yl)oxy)pyridin-2-yl]pyridine-3-methanamine was prepared from 6-iodo-3-methoxy-2-(((3R)-tetrahydrofuran-3-yl)oxy)pyridine and 3-chlorophenyl-N-(3-pyridylmethyl)amine.


MSTR 1




G1 = N / 10



G3 = alkyl <containing 1-4 C>
(opt. substd. by 1 or more G29) / 12



G4 = NH
G17 = Ph (opt. substd. by 1 or more G22)
G22 = 125



G24 = Ph (opt. substd.)
G26 = NH

Patent location:

claim 1

Note:

or pharmaceutically acceptable salts

Note:

substitution is restricted

Note:

also incorporates claims 2 and 3

Serial No.: 10/812,075

ACCESSION NUMBER: 143:1283 MARPAT Full-text
TITLE: Materials and methods using a synergistic combination of an inhibitor of mammalian Target of Rapamycin (mTOR) and an inhibitor of Platelet-Derived Growth Factor Receptor (PDGF-R) for inhibiting neointimal hyperplasia
INVENTOR(S): Hayry, Pekka Juha
PATENT ASSIGNEE(S): Oy Helsinki Transplantation R & D Ltd., Finland
SOURCE: PCT Int. Appl., 102 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:


| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---------------|--|----------|-----------------|----------|
| WO 2005049021 | A1 | 20050602 | WO 2004-EP12406 | 20041103 |
| W: | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | |
| RW: | BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | |

PRIORITY APPLN. INFO.:

US 2003-517165P 20031103

AB The present invention discloses a combination of an inhibitor of a mammalian Target of Rapamycin (mTOR) and an inhibitor of a Platelet-Derived Growth Factor Receptor (PDGF-R) for treating or preventing neointimal hyperplasia. The effect is synergistic and long-lasting. In some embodiments, the mTOR inhibitor comprises rapamycin and the PDGF-R inhibitor comprises imatinib mesylate. The inhibitors may be administered in a common mixture or as a sep. composition, they may also be administered in any number of different ways including orally, e.g., by pill, or locally, e.g., by means of a stent coating.


MSTR 2



G1 = NH2
G2 = loweralkyl
G3 = 132

132—G6

G4 = phenylene (opt. substd. by G22)
 G6 = 111



G10 = Ph (opt. substd. by 1 or more G19)
 G12 = O
 G16 = NH
 Patent location: claim 8
 Note: substitution is restricted
 Note: or salts

REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L29 ANSWER 10 OF 24 MARPAT COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 142:6552 MARPAT Full-text
 TITLE: Preparation of pyrimidine derivatives possessing cell-cycle inhibitory activity
 INVENTOR(S): Heaton, David William; Thomas, Andrew Peter
 PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astrazeneca UK Limited
 SOURCE: PCT Int. Appl., 53 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|-----------------|----------|
| WO 2004101564 | A1 | 20041125 | WO 2004-GB2019 | 20040512 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| EP 1636227 | A1 | 20060322 | EP 2004-732342 | 20040512 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR | | | | |
| JP 2007500738 | T | 20070118 | JP 2006-530484 | 20040512 |
| US 2006229329 | A1 | 20061012 | US 2005-556607 | 20051114 |
| PRIORITY APPLN. INFO.: | | | GB 2003-11274 | 20030516 |
| | | | WO 2004-GB2019 | 20040512 |

OTHER SOURCE(S): CASREACT 142:6552

AB Title compds. I [A = carbocyclyl, heterocyclyl; R1 = halo, NO2, CN, OH, etc.; p = 0-4; R2 = sulfamoyl, etc.; q = 0-2; R3 = halo, NO2, CN, OH, CF3, etc.; n = 0-2; R4-5 = H, halo, NO2, CN, OH, etc.; m = 0-4] are prepared For instance,

2-anilino-4-(6,7-dihydro-5H-pyrrolo[1,2-a]imidazol-3-yl)pyrimidine is prepared from 2-anilino-4-[1-(2-oxopyrrolidinyl)-2-(dimethylamino)ethenyl]pyrimidine (preparation given) and ammonium trifluoroacetate (NMP, 140°, 18 h). Selected examples have IC50 in the range of 13-42 nM for Cdk2-Cyclin E kinase. I are useful as antiproliferative agents.

MSTR 1



G1 = phenylene (opt. substd. by (1-4) G2)

G3 = 28 / 31 / 34 / 36 / 43

₂G6—G9—G12

₃G9—G6—G4

₃G5—G4

₃G6—G9—G13

₄G6—G9—G10—G11

G4 = 74

₇G22—G8

G6 = NH

G8 = 54 / 57 / 62 / 65

G19—G20—₅G9

G19—G9—₅G20

G19—G21—G20—₆G9

G19—G21—G9—₆G20

G9 = C(O)

G13 = Ph (opt. substd.)

G15 = NO2 / alkyl <containing 1-3 C>

Patent location:

claim 1


Note:

or pharmaceutically acceptable salts or in vivo hydrolyzable esters

Note:

also incorporates claim 12

MSTR 5



G1 = phenylene (opt. substd. by (1-4) G2)

G3 = 28 / 31 / 34 / 36 / 43

 ${}^2_8\text{G}6-\text{G}9-\text{G}12$ ${}^3_1\text{G}9-\text{G}6-\text{G}4$ ${}^3_4\text{G}5-\text{G}4$ ${}^3_6\text{G}6-\text{G}9-\text{G}13$
 ${}^4_3\text{G}6-\text{G}9-\text{G}10-\text{G}11$

G4 = 74

 ${}^7_8\text{G}22-\text{G}8$

G6 = NH

G8 = 54 / 57 / 62 / 65

 $\text{G}19-\text{G}20-{}^5_4\text{G}9$ $\text{G}19-\text{G}9-{}^5_7\text{G}20$ $\text{G}19-\text{G}21-\text{G}20-{}^6_2\text{G}9$ $\text{G}19-\text{G}21-\text{G}9-{}^6_5\text{G}20$

G9 = C(O)

G13 = Ph (opt. substd.)

G15 = NO₂ / alkyl <containing 1-3 C>

Patent location: claim 12

REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L29 ANSWER 11 OF 24 MARPAT COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 141:424210 MARPAT Full-text

TITLE: Preparation of 2-anilino-4-(imidazol-5-yl)pyrimidine
derivatives and their use as cdk (cdk2) kinase
inhibitors

INVENTOR(S): Thomas, Andrew Peter

PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astrazeneca UK Limited

SOURCE: PCT Int. Appl., 48 pp.

CODEN: PIXXD2

DOCUMENT TYPE:

Patent

LANGUAGE:

English


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|-----------------|----------|
| WO 2004101549 | A1 | 20041125 | WO 2004-GB2025 | 20040512 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| EP 1631566 | A1 | 20060308 | EP 2004-732343 | 20040512 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK | | | | |
| JP 2006528962 | T | 20061228 | JP 2006-530486 | 20040512 |
| US 2007037839 | A1 | 20070215 | US 2005-556561 | 20051114 |
| PRIORITY APPLN. INFO.: | | | GB 2003-11276 | 20030516 |
| | | | WO 2004-GB2025 | 20040512 |

AB Title compds. I [R1 = halo, NO₂, CN, OH, NH₂, carboxy, etc.; p = 0-4; R2 = sulfamoyl, etc.; q = 0-2; R3 = halo, NO₂, CN, OH, CF₃, etc.; n = 0-2; R4 = H, alk(en/yn)yl, cycloalkyl, etc.; R5 = H, halo, NO₂, CN, etc.; R6 = H, alkyl, cycloalkyl, Ph, etc.] are prepared For instance, 2-Anilino-4-[1-isopropyl-2-(N-hydroxyiminomethyl)imidazol-5-yl]pyrimidine is prepared from the corresponding aldehyde and hydroxylamine. Selected compds. of the invention exhibit IC₅₀ in the range of 1 mM to 1 nM for CDK2 kinase. I are useful for producing a cell cycle inhibitory (anti cell proliferation) effect.

MSTR 1



G1 = phenylene (opt. substd. by (1-4) G2)

G3 = 28 / 31 / 34 / 36 / 43

 ${}^2_8\text{G}6\text{---G}9\text{---G}12$ ${}_3\text{G}9\text{---G}6\text{---G}4$ ${}_3\text{G}5\text{---G}4$ ${}_3\text{G}6\text{---G}9\text{---G}13$

4^G6—G9—G10—G11

G4 = 74

7^G22—G8

G6 = NH

G8 = 54 / 57 / 62 / 65

G19—G20—^G9G19—G9—^G20G19—G21—G20—^G9G19—G21—G9—^G20

G9 = C(O)

G13 = Ph (opt. substd.)

G15 = NO2 / alkyl <containing 1-3 C>

Patent location: claim 1

Note: or pharmaceutically acceptable salts or in vivo
hydrolyzable esters

Note: also incorporates claim 12

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L29 ANSWER 12 OF 24 MARPAT COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 141:314346 MARPAT Full-textTITLE: Preparation of quinoline, tetrahydroquinazoline, and
pyrimidine derivatives as MCH antagonist for treatment
of CNS disordersINVENTOR(S): Sekiguchi, Yoshinori; Kanuma, Kosuke; Omodera,
Katsunori; Busujima, Tsuyoshi; Tran, Thuy-Anh; Han,
Sangdon; Casper, Martin; Kramer, Bryan A.; Semple,
Graeme; Zou, NingPATENT ASSIGNEE(S): Taisho Pharmaceutical Co. Ltd., Japan; Arena
Pharmaceuticals, Inc.

SOURCE: Eur. Pat. Appl., 586 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|--|------|----------|-----------------|----------|
| EP 1464335 | A2 | 20041006 | EP 2004-7651 | 20040330 |
| EP 1464335 | A3 | 20070509 | | |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK | | | | |
| US 2005197350 | A1 | 20050908 | US 2004-812075 | 20040330 |
| AU 2004226049 | A1 | 20041014 | AU 2004-226049 | 20040331 |
| CA 2518913 | A1 | 20041014 | CA 2004-2518913 | 20040331 |
| WO 2004087669 | A1 | 20041014 | WO 2004-JP4624 | 20040331 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, | | | | |

CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
 RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG


| | | | | |
|----------------|---|----------|------------------|----------|
| JP 2004300156 | A | 20041028 | JP 2004-107965 | 20040331 |
| BR 2004008910 | A | 20060321 | BR 2004-8910 | 20040331 |
| CN 1798736 | A | 20060705 | CN 2004-80014547 | 20040331 |
| IN 2005KN01805 | A | 20061201 | IN 2005-KN1805 | 20050912 |
| NO 2005004999 | A | 20051107 | NO 2005-4999 | 20051027 |

PRIORITY APPLN. INFO.:


| | |
|-----------------|----------|
| US 2003-458530P | 20030331 |
| US 2003-495911P | 20030819 |
| US 2003-510186P | 20031009 |
| US 2003-530360P | 20031216 |
| WO 2004-JP4624 | 20040331 |

AB Title compds. I, II, and III [wherein R1 = (un)substituted (cyclo)alkyl, (cyclo)alkenyl, alkynyl, aryl; R2 = H, halo, OH, carboxy, carbamoyl, amino, (un)substituted alkyl, alkoxy; T = independently H, halo, OH, carboxy, carbamoyl, amino, cyano, NO₂, alkenyl, alkynyl, cycloalkyl, (un)substituted alkyl, alkoxy; p = 0-5; L = aminocycloalkylideneamino, etc.; Y = bond, CH₂, CO₂, OCO, SO₂, CO, CS, CONH, CSNH, etc.; with provisos; and pharmaceutically acceptable salts, hydrates, or solvates thereof] were prepared as antagonists of melanin concentrating hormone (MCH), an endogenous ligand of G-protein coupled receptors (GPCRs). Examples include solution and solid phase general synthetic methods and phys. data for nearly 3400 invention compds. In addition, all exemplified compds. were assayed using high throughput functional screening to detect intracellular Ca²⁺ concns. for accessing GPCR activation. For instance, reaction of 2,4-dichloro-6-methylpyrimidine with dimethylamine gave 2-chloro-4-(dimethylamino)-6-methylpyrimidine (40%), which was coupled with cis-(4-aminocyclohexyl)carbamic acid tert-Bu ester (60%). Deprotection (72%), amidation, and workup provided the benzamide IV•TFA. The latter demonstrated MCH antagonist activity with an IC₅₀ value of 7.6 nM. Thus, pharmaceutical compns. comprising I are useful for the prophylaxis or treatment of improving memory function, sleeping and arousal, anxiety, depression, mood disorders, seizure, obesity, diabetes, appetite and eating disorders, cardiovascular disease, hypertension, dyslipidemia, myocardial infarction, binge eating disorders including bulimia, anorexia, mental disorders including manic depression, schizophrenia, delirium, dementia, stress, cognitive disorders, attention deficit disorder, substance abuse disorders, and dyskinesias including Parkinson's disease, epilepsy, and addiction (no data). This is part I of three in a series covering the patent.

MSTR 1C




G1 = 32-5 34-2




G6 = alkyl <containing 1-5 C>
(opt. substd. by 1 or more G3)

G7 = 58-1 61-3 / 123-1 125-3



G8 = NH

G10 = 66-58 69-60



G12 = 121



G13 = O

G16 = m-C₆H₄Me

G36 = NH₂

Patent location:

claim 1

Note:

substitution is restricted

Note:

additional substitution also claimed

L29 ANSWER 13 OF 24 MARPAT COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 141:38625 MARPAT Full-text

TITLE: Preparation of Chk-, pdk- and akt-inhibitory pyrimidines

INVENTOR(S): Bryant, Judi; Kochanny, Monica; Yuan, Shendong; Khim, Seock-Kuy; Buckman, Brad; Arnaiz, Damian; Boemer, Ulf; Briem, Hans; Esperling, Peter; Huwe, Christoph; Kuhnke, Joachim; Schaefer, Martina; Wortmann, Lars; Kosemund, Dirk; Eckle, Emil; Feldman, Richard; Phillips, Gary

PATENT ASSIGNEE(S): Schering Aktiengesellschaft, Germany

SOURCE: PCT Int. Appl., 293 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent


LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1


PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|------------------|----------|
| WO 2004048343 | A1 | 20040610 | WO 2003-EP13443 | 20031128 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| CA 2502970 | A1 | 20040610 | CA 2003-2502970 | 20031128 |
| AU 2003288198 | A1 | 20040618 | AU 2003-288198 | 20031128 |
| US 2004186118 | A1 | 20040923 | US 2003-722591 | 20031128 |
| EP 1565446 | A1 | 20050824 | EP 2003-780086 | 20031128 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK | | | | |
| BR 2003016680 | A | 20051018 | BR 2003-16680 | 20031128 |
| CN 1717396 | A | 20060104 | CN 2003-80104544 | 20031128 |
| JP 2006508997 | T | 20060316 | JP 2004-554522 | 20031128 |
| IN 2005DN01603 | A | 20070202 | IN 2005-DN1603 | 20050420 |
| NO 2005003144 | A | 20050627 | NO 2005-3144 | 20050627 |
| PRIORITY APPLN. INFO.: | | | EP 2002-26607 | 20021128 |
| | | | WO 2003-EP13443 | 20031128 |
| AB The title compds. [I; A, B = CN, halo, H, OH, etc.; X = O, (un)substituted NH; R1 = H, halo, CH2OH, alkyl, etc.; R2 = H, (un)substituted NHCO-aryl or alkyl] which are inhibitors of kinases useful as medications for treating various diseases, were prepared E.g., a multi-step synthesis of 5-bromo-4-[2-(1H-imidazol-4-yl)ethylamino]-2-(4-pyrrolidin-1-ylmethylphenylamino)pyrimidine, starting from 5-bromouracil, was given. Biol. data for inhibition of Akt-2, Chk-1, and VEGFR-II (KDR) were given. The pharmaceutical composition comprising the compds. I is claimed. | | | | |

MSTR 1




G1 = 302




G25 = alkyl <containing 1-6 C>

G28 = 136



G42 = 266-7 267-10 268-9



G43 = Ph

Patent location:

claim 1

Note:

and isotopes, solvates, polymorphs, or
pharmaceutically acceptable salts

Note:

additional oxo group substitution and ring
formation also claimed

Stereochemistry:

or diastereomers or enantiomers

REFERENCE COUNT:

2

THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L29 ANSWER 14 OF 24 MARPAT COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 137:201334 MARPAT Full-textTITLE: Preparation of N-phenyl 4-heterocyclylpyrimidin-2-
amines for inhibition of cell-proliferation

INVENTOR(S): Thomas, Andrew Peter

PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astrazeneca UK Limited

SOURCE: PCT Int. Appl., 76 pp.

CODEN: PIXXD2

DOCUMENT TYPE:

Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|-----------------|----------|
| WO 2002066481 | A1 | 20020829 | WO 2002-GB603 | 20020212 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW | | | | |
| RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| CA 2438646 | A1 | 20020829 | CA 2002-2438646 | 20020212 |
| AU 2002231960 | A1 | 20020904 | AU 2002-231960 | 20020212 |
| EP 1362050 | A1 | 20031119 | EP 2002-712053 | 20020212 |
| EP 1362050 | B1 | 20050202 | | |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR | | | | |

Serial No.: 10/812,075


| | | | | |
|------------------------|----|----------|-----------------|----------|
| BR 2002007294 | A | 20040302 | BR 2002-7294 | 20020212 |
| JP 2004521916 | T | 20040722 | JP 2002-565995 | 20020212 |
| CN 1524081 | A | 20040825 | CN 2002-808167 | 20020212 |
| AT 288436 | T | 20050215 | AT 2002-712053 | 20020212 |
| NZ 527367 | A | 20050429 | NZ 2002-527367 | 20020212 |
| PT 1362050 | T | 20050531 | PT 2002-712053 | 20020212 |
| ES 2236494 | T3 | 20050716 | ES 2002-2712053 | 20020212 |
| ZA 2003006081 | A | 20041117 | ZA 2003-6081 | 20030806 |
| US 2004097506 | A1 | 20040520 | US 2003-467886 | 20030813 |
| US 6844341 | B2 | 20050118 | | |
| NO 2003003635 | A | 20030815 | NO 2003-3635 | 20030815 |
| PRIORITY APPLN. INFO.: | | | GB 2001-3926 | 20010217 |
| | | | WO 2002-GB603 | 20020212 |

AB The title compds. [I; ring A = (un)substituted imidazo[1,2-a]pyrazin-3-yl, imidazo[1,2-a]pyrimidin-3-yl, imidazo[1,2-b]pyridazin-3-yl, etc.; R1 = halo, NO2, CN, etc.; n = 0-2; R3 = halo, NO2, CN, etc.; p = 0-4; R4 = EB; B = (un)substituted alkyl, Ph, heterocyclyl, etc.; E = a direct bond, O, CO, etc.; q = 0-2], useful as medicaments, particularly medicaments for producing a cell cycle inhibitory (anti-cell-proliferation) effect in a warm-quest-blooded animal, such as man, were prepared and formulated. Thus, treating 2-anilino-4-(imidazo[1,2-b]pyridazin-3-yl)pyrimidine (preparation given) dissolved in thionyl chloride, with chlorosulfonic acid, followed by reaction of the intermediate with methanolic ammonia afforded 64% I [A = imidazo[1,2-b]pyridazin-3-yl; R1, R3 = H; R4 = 4-sulfamoyl]. In general, cyclin E/CDK2 activity possessed by compds. I may be demonstrated at IC50's in range 250 μ M to 1 nM.


MSTR 1

G6—G13

G1 = NO2 / alkyl <containing 1-6 C> (opt. substd.)
G4 = 69



G6 = 7



G13 = Ph (opt. substd. by (1-5) G14)
G14 = (0-2) G4

G15 = Ph (opt. substd.)

Patent location:

claim 1

Note:

or pharmaceutically acceptable salts or
hydrolysable esters

Note:

also incorporates claim 14, formulas III, IV, VI,
and IX

REFERENCE COUNT:

2

THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L29 ANSWER 15 OF 24 MARPAT COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER:

137:201324 MARPAT Full-text

TITLE:

Preparation of 4-(imidazo[1,2-a]pyrid-3-
yl)pyrazolo[2,3-a]pyrid-3-yl)-2-arylamino pyrimidines
for the treatment of GSK3-related disorders

INVENTOR(S):

Berg, Stefan; Bhat, Ratan; Hellberg, Sven

PATENT ASSIGNEE(S):

Astrazeneca AB, Swed.

SOURCE:

PCT Int. Appl., 71 pp.

CODEN: PIXXD2

DOCUMENT TYPE:

Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|-----------------|----------|
| WO 2002066480 | A2 | 20020829 | WO 2002-SE270 | 20020218 |
| WO 2002066480 | A3 | 20040401 | | |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW | | | | |
| RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| CA 2435177 | A1 | 20020829 | CA 2002-2435177 | 20020218 |
| AU 2002232346 | A1 | 20020904 | AU 2002-232346 | 20020218 |
| BR 2002007096 | A | 20040120 | BR 2002-7096 | 20020218 |
| EP 1423388 | A2 | 20040602 | EP 2002-712572 | 20020218 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR | | | | |
| JP 2004522777 | T | 20040729 | JP 2002-565994 | 20020218 |
| NZ 527009 | A | 20060428 | NZ 2002-527009 | 20020218 |
| CN 1823064 | A | 20060823 | CN 2002-805252 | 20020218 |
| ZA 2003006175 | A | 20041108 | ZA 2003-6175 | 20030808 |
| NO 2003003677 | A | 20031002 | NO 2003-3677 | 20030819 |
| US 2004106574 | A1 | 20040603 | US 2003-468605 | 20030819 |
| US 7078410 | B2 | 20060718 | | |

PRIORITY APPLN. INFO.:


US 2001-269903P 20010220
WO 2002-SE270 20020218

AB

The title compds. [I; ring A = imidazo[1,2-a]pyrid-3-yl or pyrazolo[2,3-a]pyrid-3-yl; R2 = halo, NO2, CN, etc.; m = 0-5; R1 = halo, NO2, CN, etc.; n = 0-2; ring B = Ph, Ph fused to cycloalkyl; R3 = halo, NO2, CN, etc.; p = 0-4; R4 = EA (A = H, alkyl, Ph, etc.; E = a direct bond, O, CO, etc.); q = 0-2], useful in the treatment and/or prophylaxis of conditions associated with glycogen synthase kinase-3, were prepared and formulated. Thus, reacting 3-chloroaniline with 4-(2-methylimidazo[1,2-a]pyrid-3-yl)-2-

methylthiopyrimidine (preparation given) in the presence of NaH in NMP afforded 21% II. Typical K_i values for the compds. I are in the range of about 0.001 to about 10,100 nM in human GSK3 β assay.

MSTR 1



G4 = NO₂ / alkyl <containing 1 or more C>
(opt. substd.)
G6 = 50

⁵G²⁰-G⁹

G9 = 93

⁹G¹⁷-⁹G¹⁹

G17 = 95-50 96-94

⁹G¹⁸-⁹G⁽⁰⁾

G18 = NH
G19 = Ph (opt. substd.)
G20 = phenylene (opt. substd. by 1 or more G7)
Patent location: claim 1
Note: or pharmaceutically acceptable salts

L29 ANSWER 16 OF 24 MARPAT COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 136:247599 MARPAT Full-text
TITLE: Preparation of imidazolo-5-yl-2-anilino-pyrimidines as agents for the inhibition of the cell proliferation
INVENTOR(S): Breault, Gloria Anne; Newcombe, Nicholas John; Thomas, Andrew Peter
PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astrazeneca UK Limited
SOURCE: PCT Int. Appl., 108 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---------------|------|----------|-----------------|----------|
| WO 2002020512 | A1 | 20020314 | WO 2001-GB3864 | 20010830 |
| WO 2002020512 | A9 | 20040506 | | |

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

| | | | | |
|---------------|----|----------|-----------------|----------|
| CA 2417148 | A1 | 20020314 | CA 2001-2417148 | 20010830 |
| AU 200184192 | A | 20020322 | AU 2001-84192 | 20010830 |
| BR 2001013496 | A | 20030701 | BR 2001-13496 | 20010830 |
| EP 1351958 | A1 | 20031015 | EP 2001-963159 | 20010830 |
| EP 1351958 | B1 | 20040616 | | |

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR


| | | | | |
|---------------|----|----------|------------------|----------|
| HU 200302922 | A2 | 20031229 | HU 2003-2922 | 20010830 |
| HU 200302922 | A3 | 20070228 | | |
| JP 2004508365 | T | 20040318 | JP 2002-525133 | 20010830 |
| JP 3523641 | B2 | 20040426 | | |
| AT 269327 | T | 20040715 | AT 2001-963159 | 20010830 |
| NZ 523787 | A | 20040924 | NZ 2001-523787 | 20010830 |
| PT 1351958 | T | 20040930 | PT 2001-963159 | 20010830 |
| ES 2221904 | T3 | 20050116 | ES 2001-1963159 | 20010830 |
| EE 200300088 | A | 20050215 | EE 2003-88 | 20010830 |
| RU 2284327 | C2 | 20060927 | RU 2003-109612 | 20010830 |
| TW 242559 | B | 20051101 | TW 2001-90122494 | 20010911 |
| ZA 2003000612 | A | 20040422 | ZA 2003-612 | 20030122 |
| BG 107579 | A | 20031031 | BG 2003-107579 | 20030221 |
| NO 2003001006 | A | 20030304 | NO 2003-1006 | 20030304 |
| US 2004014776 | A1 | 20040122 | US 2003-363655 | 20030304 |
| US 6969714 | B2 | 20051129 | | |
| HK 1057553 | A1 | 20041231 | HK 2004-100403 | 20040119 |
| US 2006004033 | A1 | 20060105 | US 2005-169197 | 20050629 |

PRIORITY APPLN. INFO.:

| | |
|----------------|----------|
| GB 2000-21726 | 20000905 |
| WO 2001-GB3864 | 20010830 |
| US 2003-363655 | 20030304 |

AB Title compds. I [R1 = halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, alk(en/yn)yl, alkoxy; p = 0-4; R2 = sulfamoyl, Ra-Rb; q = 0-2; p + q = 0-5; R3 = halo, nitro, cyano, hydroxy, trifluoromethyl, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulfamoyl, alk(en/yn)yl, alkoxy, alkanoyl, etc.; n = 0-2, R4 = H, alk(en/yn)yl, cycloalkyl, Ph, etc.; R5-6 = H, halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulfamoyl, alk(en/yn)yl, alkoxy, etc.; Ra = alk(en/yn)yl, cycloalkyl, Ph, heterocyclyl, phenyl-alkyl, etc.; Rb = C(O), amido, carboxamido, etc.] were prepared For instance, phenylguanidine hydrogen carbonate was condensed with 5-(3-dimethylaminoprop-2-en-1-oyl)-1-methylimidazole (i-PrOH, NaOMe, reflux, 3 h) to give II in 64% yield. The CDK2 inhibitory activity of II was measured as IC50 = 0.146 μ M.

MSTR 1



G1 = Ph (opt. substd. by 1 or more G2)
 G2 = (up to 2) G4
 G4 = 11 / 13 / 18

$1G6-G5$ $1G7-G8-G5$ $1G8-G7-G5$

G5 = Ph (opt. substd.)
 G7 = NH
 G8 = C(O)
 G12 = NO₂ / alkyl <containing 1 or more C>
 (opt. substd.)

Patent location: claim 1
 Note: or pharmaceutically acceptable salts or in vivo
 hydrolysable esters

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L29 ANSWER 17 OF 24 MARPAT COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 134:193444 MARPAT Full-text

TITLE: Preparation of imidazo[1,2-a]pyridinylpyrimidines and
 pyrazolo[2,3-a]pyridinylpyrimidines as inhibitors of
 CDK2, CDK4, and CDK6 cell cycle kinases.

INVENTOR(S): Thomas, Andrew Peter; Breault, Gloria Anne; Beattie,
 John Franklin; Jewsbury, Phillip John

PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astrazeneca UK Limited

SOURCE: PCT Int. Appl., 81 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:


| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---------------|--|----------|-----------------|----------|
| WO 2001014375 | A1 | 20010301 | WO 2000-GB3139 | 20000815 |
| W: | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW | | | |
| RW: | GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | |
| CA 2376293 | A1 | 20010301 | CA 2000-2376293 | 20000815 |
| BR 2000013476 | A | 20020430 | BR 2000-13476 | 20000815 |

Serial No.: 10/812,075

| | | | | |
|--|----|----------|----------------|----------|
| EP 1214318 | A1 | 20020619 | EP 2000-953319 | 20000815 |
| EP 1214318 | B1 | 20031008 | | |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL | | | | |
| HU 200202494 | A2 | 20021028 | HU 2002-2494 | 20000815 |
| JP 2003507478 | T | 20030225 | JP 2001-518706 | 20000815 |
| AU 757639 | B2 | 20030227 | AU 2000-65833 | 20000815 |
| EE 200200080 | A | 20030616 | EE 2002-80 | 20000815 |
| AT 251623 | T | 20031015 | AT 2000-953319 | 20000815 |
| PT 1214318 | T | 20040227 | PT 2000-953319 | 20000815 |
| ES 2208397 | T3 | 20040616 | ES 2000-953319 | 20000815 |
| NZ 516740 | A | 20040924 | NZ 2000-516740 | 20000815 |
| RU 2248976 | C2 | 20050327 | RU 2002-107128 | 20000815 |
| ZA 2002000028 | A | 20030402 | ZA 2002-28 | 20020102 |
| IN 2002MN00027 | A | 20050318 | IN 2002-MN27 | 20020109 |
| BG 106383 | A | 20020930 | BG 2002-106383 | 20020204 |
| NO 2002000832 | A | 20020412 | NO 2002-832 | 20020220 |
| NO 322818 | B1 | 20061211 | | |
| US 6855719 | B1 | 20050215 | US 2002-69019 | 20020221 |
| HK 1045510 | A1 | 20040319 | HK 2002-107002 | 20020925 |
| PRIORITY APPLN. INFO.: | | | GB 1999-19778 | 19990821 |
| | | | WO 2000-GB3139 | 20000815 |

AB Title compds. [I; A = imidazo[1,2-a]pyrid-3-yl, pyrazolo[2,3-a]pyrid-3-yl; R1 = halo, NO₂, cyano, OH, CF₃, OCF₃, amino, CO₂H, sulfamoyl, (substituted) alkyl, alkenyl, alkynyl, alkoxy, alkanoyl, alkanoyloxy, Ph, heterocyclyl, etc.; R2 = halo, NO₂, cyano, OH, CF₃, OCF₃, amino, CO₂H, SH, carbamoyl, sulfamoyl, (substituted) alkyl, alkenyl, alkynyl, alkoxy, Ph, heterocyclyl, PhS, etc.; R3 = halo, NO₂, cyano, OH, amino, CO₂H, carbamoyl, SH, sulfamoyl, alkenyl, alkynyl; m = 0-5; n = 0-2; Ring B = Ph or Ph fused to a C5-7 cycloalkyl ring; p = 0-4; R4 = AE; A = (substituted) alkyl, Ph, heterocyclyl, cycloalkyl, phenylalkyl, heterocyclylalkyl, cycloalkylcycloalkyl; E = bond, O, CO, CO₂, NRaCO, NRa, S, SO, SO₂, SO₂NRa; q = 0-2; p+q≤5], were prepared Thus, NaH was added to 3-chloroaniline in N-methylpyrrolidone; after 30 min. 4-(2-methylimidazo[1,2-a]pyridin-3-yl)-2-methylthiopyrimidine (preparation given) in N-methylpyrrolidone was added and the mixture was heated at 150° for 3 h to give 21% 2-(3-chloroanilino)-4-(2-methylimidazo[1,2-a]pyrid-3-yl)pyrimidine. 2-[4-(2-Diethylaminoethoxy)anilino]-4-(imidazo[1,2-a]pyrid-3-yl)pyrimidine showed CDK2 inhibitory activity with IC₅₀ = 0.17 μM.

MSTR 1



G1 = NO₂ / alkyl <containing 1 or more C>
(opt. substd.)
G6 = Ph (opt. substd. by (1-4) G7)
G7 = (up to 2) G9
G9 = 59

⁵G¹⁵-C(O)-G¹⁴

G14 = Ph (opt. substd.)
G15 = NH
Patent location: claim 1
Note: or pharmaceutically acceptable salts or in vivo
hydrolysable esters


MSTR 3

G20—G6

G1 = NO2 / alkyl <containing 1 or more C>
(opt. substd.)
G6 = Ph (opt. substd. by (1-4) G7)
G7 = (up to 2) G9
G9 = 59

$G15-C(O)-G14$

G14 = Ph (opt. substd.)
G15 = NH
G20 = 7



Patent location: claim 9

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L29 ANSWER 18 OF 24 MARPAT COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 132:347593 MARPAT Full-text
TITLE: Pyrimidinylbenzimidazole and triazinylbenzimidazole
derivatives and agricultural/horticultural fungicides
INVENTOR(S): Shibata, Masaru; Kawai, Kiyoshi; Makiyara, Takechi;
Yonekura, Norihisa; Kawashima, Takahiro; Sakai,
Junetsu; Muramatsu, Norimichi
PATENT ASSIGNEE(S): Kumiai Chemical Industry Co., Ltd., Japan; Ihara
Chemical Industry Co., Ltd.
SOURCE: PCT Int. Appl., 120 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|----------|-------------------|----------|
| WO 2000029404 | A1 | 20000525 | WO 1999-JP6364 | 19991115 |
| W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW | | | | |
| RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | | |
| JP 2000212181 | A | 20000802 | JP 1999-322069 | 19991112 |
| CA 2350968 | A1 | 20000525 | CA 1999-2350968 | 19991115 |
| BR 9915401 | A | 20010814 | BR 1999-15401 | 19991115 |
| EP 1132387 | A1 | 20010912 | EP 1999-972212 | 19991115 |
| EP 1132387 | B1 | 20050928 | | |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO | | | | |
| HU 200104171 | A2 | 20020228 | HU 2001-4171 | 19991115 |
| TR 200101381 | T2 | 20020521 | TR 2001-200101381 | 19991115 |
| AU 755538 | B2 | 20021212 | AU 2000-11805 | 19991115 |
| RU 2222536 | C2 | 20040127 | RU 2001-116600 | 19991115 |
| AT 305465 | T | 20051015 | AT 1999-972212 | 19991115 |
| JP 2000302780 | A | 20001031 | JP 2000-38498 | 20000216 |
| JP 3820337 | B2 | 20060913 | | |
| US 6576631 | B1 | 20030610 | US 2001-830578 | 20010508 |
| ZA 2001003758 | A | 20020319 | ZA 2001-3758 | 20010509 |
| US 2004023966 | A1 | 20040205 | US 2003-383693 | 20030310 |
| US 6872729 | B2 | 20050329 | | |
| PRIORITY APPLN. INFO.: | | | JP 1998-343614 | 19981117 |
| | | | JP 1999-39566 | 19990218 |
| | | | WO 1999-JP6364 | 19991115 |
| | | | US 2001-830578 | 20010508 |
| AB | Title compds. I (A = N, CR3; R1, R2 = H, halo, alkyl, alkenyl, etc.; R3 = H, alkyl, alkoxy, halo; X = H, halo, nitro, cyano, etc.; Y = halo, nitro, cyano, alkyl, etc.; n = 0, 1, 2, 3), useful as agricultural/horticultural fungicides, are prepared Thus, reaction of benzimidazole with 2-chloro-4-methoxypyrimidine in DMF in the presence of NaH gave 1-(4-methoxypyrimidin-2-yl)benzimidazole (II). II at 500 ppm gave >80% control against Erysiphe graminis on barley seedlings. | | | |

MSTR 2



G1 = 16

16—G2

G2 = alkyl <containing 1-6 C>
 G3 = dialkylamino <each alkyl containing 1-4 C>
 G7 = Ph (opt. substd. by 1 or more G6)
 G9 = 30

HN—C(O)—G7

Patent location: claim 6
 Note: substitution is restricted

REFERENCE COUNT: 53 THERE ARE 53 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L29 ANSWER 19 OF 24 MARPAT COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 132:44977 MARPAT Full-text

TITLE: Benzamidine derivatives substituted by cyclic amino
 acid and cyclic hydroxy acid derivatives and their use
 as anticoagulants

INVENTOR(S): Kochanny, Monica; Morrissey, Michael M.; Ng, Howard P.

PATENT ASSIGNEE(S): Berlex Laboratories, Inc., USA

SOURCE: U.S., 31 pp., Cont.-in-part of U.S. Ser. No. 713,066.
 CODEN: USXXAM

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:


| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|-----------------|----------|
| US 6008234 | A | 19991228 | US 1997-920319 | 19970827 |
| CA 2264521 | A1 | 19980319 | CA 1997-2264521 | 19970911 |
| WO 9811094 | A1 | 19980319 | WO 1997-EP4961 | 19970911 |
| W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW | | | | |
| RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG | | | | |
| AU 9743843 | A | 19980402 | AU 1997-43843 | 19970911 |
| AU 723999 | B2 | 20000907 | | |
| EP 929547 | A1 | 19990721 | EP 1997-942015 | 19970911 |
| EP 929547 | B1 | 20021127 | | |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO | | | | |
| CN 1234798 | A | 19991110 | CN 1997-198664 | 19970911 |
| HU 9903184 | A2 | 20000228 | HU 1999-3184 | 19970911 |
| HU 9903184 | A3 | 20010628 | | |
| JP 2001500147 | T | 20010109 | JP 1998-513257 | 19970911 |
| JP 3565864 | B2 | 20040915 | | |

Serial No.: 10/812,075


| | | | | |
|------------------------|----|----------|----------------|----------|
| AT 228513 | T | 20021215 | AT 1997-942015 | 19970911 |
| PT 929547 | T | 20030331 | PT 1997-942015 | 19970911 |
| ES 2188979 | T3 | 20030701 | ES 1997-942015 | 19970911 |
| KR 2000036017 | A | 20000626 | KR 1999-701989 | 19990310 |
| NO 9901206 | A | 19990511 | NO 1999-1206 | 19990311 |
| MX 9902396 | A | 20000331 | MX 1999-2396 | 19990311 |
| US 6177473 | B1 | 20010123 | US 1999-439065 | 19991112 |
| US 6232325 | B1 | 20010515 | US 1999-438354 | 19991112 |
| US 6265404 | B1 | 20010724 | US 1999-438270 | 19991112 |
| CN 1338454 | A | 20020306 | CN 2001-121736 | 20010703 |
| PRIORITY APPLN. INFO.: | | | US 1996-713066 | 19960912 |
| | | | US 1997-920319 | 19970827 |
| | | | WO 1997-EP4961 | 19970911 |

AB Benzamidine derivs. substituted by cyclic amino acid and cyclic hydroxy acid derivs. are provided which are useful as anticoagulants. Also disclosed are pharmaceutical compns. containing the compds. of the invention, and methods of using the compds. to treat disease-states characterized by thrombotic activity.


MSTR 1




G1 = 11



G2 = Ph
G8 = 37



G15 = 59-7 58-45 57-23



G23 = alkyl <containing 1-6 C>
(opt. substd. by 1 or more G18)
G26 = 255

~~253~~²⁵⁷—G28—G29—G30

G27 = NH
G41 = (1) N / 294

~~294~~—G23

Derivative: and pharmaceutically acceptable salts
Patent location: claim 1
Stereochemistry: or stereoisomers or salts

REFERENCE COUNT: 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L29 ANSWER 20 OF 24 MARPAT COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 131:37806 MARPAT Full-text
TITLE: Pyrimidine compound dye and thermal-transfer printing
material and ink-jet printing liquid using same
INVENTOR(S): Ohya, Hidenobu; Kida, Shuji; Kaneko, Manabu
PATENT ASSIGNEE(S): Konica Co., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 15 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:


| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------------------------|------|----------|-----------------|----------|
| JP 11152417 | A | 19990608 | JP 1997-336535 | 19971120 |
| PRIORITY APPLN. INFO.: | | | JP 1997-336535 | 19971120 |

AB The title dye has the general formula B:DA [A = pyrimidine ring having at least NR₁R₂ as a substituent, A links to D at the C atom in the pyrimidine ring; B = coupler component which links to D at its active point; D = N or CH; R₁, R₂ = H, (substituted) alkyl, (substituted) aryl, (substituted) heterocycle, R₁ and R₂ may link each other to form a ring]. A thermal-transfer printing material possessing a layer containing the dye on a support and an ink-jet printing liquid containing the dye are also claimed. The material and the printing liquid produce light-fast images.

MSTR 1


G4—~~G5~~—G1—~~G2~~

G1 = 5-2 7-4



G2 = NH2

G4 = 141



G5 = N

G6 = Me

G18 = Ph

Patent location: claim 1

L29 ANSWER 21 OF 24 MARPAT COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 128:230376 MARPAT Full-text

TITLE: Benzamidine derivatives substituted by cyclic amino acid or cyclic hydroxy acid derivatives, and their use as anticoagulants

INVENTOR(S): Kochanny, Monica; Morrissey, Michael M.; Ng, Howard P.

PATENT ASSIGNEE(S): Schering A.-G., Germany

SOURCE: PCT Int. Appl., 79 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:


| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|-----------------|----------|
| WO 9811094 | A1 | 19980319 | WO 1997-EP4961 | 19970911 |
| W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW | | | | |
| RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG | | | | |
| US 6008234 | A | 19991228 | US 1997-920319 | 19970827 |
| CA 2264521 | A1 | 19980319 | CA 1997-2264521 | 19970911 |
| AU 9743843 | A | 19980402 | AU 1997-43843 | 19970911 |
| AU 723999 | B2 | 20000907 | | |
| EP 929547 | A1 | 19990721 | EP 1997-942015 | 19970911 |
| EP 929547 | B1 | 20021127 | | |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO | | | | |

Serial No.: 10/812,075


| | | | | |
|------------------------|----|----------|----------------|----------|
| JP 2001500147 | T | 20010109 | JP 1998-513257 | 19970911 |
| JP 3565864 | B2 | 20040915 | | |
| AT 228513 | T | 20021215 | AT 1997-942015 | 19970911 |
| NO 9901206 | A | 19990511 | NO 1999-1206 | 19990311 |
| MX 9902396 | A | 20000331 | MX 1999-2396 | 19990311 |
| PRIORITY APPLN. INFO.: | | | US 1996-713066 | 19960912 |
| | | | US 1997-920319 | 19970827 |
| | | | WO 1997-EP4961 | 19970911 |

AB The invention is directed to benzamidine derivs. substituted by cyclic amino acid and cyclic hydroxy acid derivs., which are represented by seven general formulas, e.g., I [A = CR⁸ or N; Z¹, Z² = O, NR⁹, S, S(O), S(O)₂, or OCH₂; R¹, R⁴ = H, halo, alkyl, NO₂, OR⁹, CO₂R⁹, NR⁹R¹⁰ or derivs.; R² = C(:NH)NH₂, C(:NH)NHOR⁹, C(:NH)NHCO₂R¹², C(:NH)NHCOR⁹, etc.; R³ = H, alkyl, halo, haloalkyl, NO₂, ureido, guanidino, OR⁹, C(:NH)NH₂ or derivs., etc.; R⁵, R⁶ = H, halo, alkyl, haloalkyl, NR⁹R¹⁰, CO₂R⁹, etc.; R⁷ = NR⁹(CR⁹R¹⁰)O-4R¹³, O(CR⁹R¹⁰)O-4R¹³, or NR¹⁴R¹⁵; R⁸ = H, alkyl, halo; R⁹, R¹⁰ = H, alkyl, (un)substituted aryl or aralkyl; R¹² = alkyl, (un)substituted aryl or aralkyl; R¹³ = (un)substituted carbocycle; R¹⁴, R¹⁵ = (un)substituted heterocycle]. The compds. are useful as anticoagulants. This invention is also directed to pharmaceutical compns. containing the compds., and their use to treat thrombotic disease states. For example, pentafluoropyridine underwent a sequence of: (1) amination in the 4-position by Et 1-amino-1-cyclopentanecarboxylate-HCl (82%); (2) N-methylation of the amino group (65%); (3) etherification in the 2-position with 2-(benzyloxy)-5-cyanophenol (60%); (4) etherification in the 6-position with 3-(1-methylimidazolin-2-yl)phenol; and (5) Pinner reaction of the nitrile with concomitant debenzylation, to give title compound II (isolated as the CF₃CO₂H salt).

MSTR 1



G1 = 10-3 12-5 14-8




G2 = 15 / N




G3 = alkyl <containing 1-6 C>
(opt. substd. by 1 or more G8)
G4 = Ph


G12 = 72




G14 = 90-3 89-84 88-1




G16 = 215




G17 = 220



G24 = 268-4 274-259



G31 = 289



| | |
|------------------|--------------------------------------|
| Derivative: | or pharmaceutically acceptable salts |
| Patent location: | claim 1 |
| Note: | substitution is restricted |
| Stereochemistry: | single stereoisomer or mixture |

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L29 ANSWER 22 OF 24 MARPAT COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 119:273400 MARPAT Full-text
 TITLE: Continuous reaction of halopyrimidines with amines
 INVENTOR(S): Arnold, Siegbert; Frosch, Hans Georg; Hoppe, Manfred; Muellers, Wolfgang; Sommer, Richard

PATENT ASSIGNEE(S): Bayer A.-G., Germany
 SOURCE: Eur. Pat. Appl., 26 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------------------------|------|----------|-----------------|----------|
| EP 542079 | A2 | 19930519 | EP 1992-118736 | 19921102 |
| EP 542079 | A3 | 19940817 | | |
| EP 542079 | B1 | 19970723 | | |
| R: CH, DE, FR, GB, LI | | | | |
| DE 4137291 | A1 | 19930519 | DE 1991-4137291 | 19911113 |
| JP 05222306 | A | 19930831 | JP 1992-321425 | 19921106 |
| US 5420255 | A | 19950530 | US 1994-200865 | 19940222 |
| PRIORITY APPLN. INFO.: | | | DE 1991-4137291 | 19911113 |
| | | | US 1992-970897 | 19921103 |

AB Reactive dyes are obtained by continuous condensation of halopyrimidines with aqueous amine solns. or dispersions using sep. feeding of the reactants, and removal of the product; the reactants are simultaneously added to the reactor with intensive stirring, e.g., at Reynolds number ≥ 2500 . Thus, 9 kg/h 5-chloro-2,4,6-trifluoropyrimidine (I) at 20° and 171 L/h aqueous solution at 40° containing 12.9 kg Na 7-amino-4-hydroxy-2-naphthalenesulfonate and 2.1 kg NaF were introduced (with I pressure drop 35 bars) to a jet nozzle reactor and the product at 0° was coupled with diazotized 2-amino-5-methoxybenzenesulfonic acid to give an azo dye. The dye provided clear scarlet shades on cotton.

MSTR 3A



G1 = 757-1 758-3 / 759-1 761-3 / 762-1 764-3 /
 765-1 766-3 / 767-1 769-3

757-1 758-3 759-1 761-3 762-1 764-3 765-1 766-3 767-1 769-3


G3 = Ph (opt. substd. by 1 or more G4)
 G5 = pyrimidinyl (substd. by 1 or more G6)
 G6 = NO2 / Me
 G17 = NH
 G52 = C(O)
 G55 = phenylene (opt. substd. by (up to 2) SO3H)
 Patent location: claim 5

MSTR 1

G5—G7

Patent location: claim 5

MSTR 3A




G1 = 757-1 758-3 / 759-1 761-3 / 762-1 764-3 /
765-1 766-3 / 767-1 769-3

~~757-1 758-3~~ ~~759-1 761-3~~ ~~762-1 764-3~~ ~~765-1 766-3~~ ~~767-1 769-3~~

G3 = Ph (opt. substd. by 1 or more G4)
G5 = pyrimidinyl (substd. by 1 or more G6)
G6 = NO2 / Me
G17 = NH
G52 = C(O)
G55 = phenylene (opt. substd. by (up to 2) SO3H)
Patent location: claim 5


MSTR 3B



G1 = 757-1 758-3 / 759-1 761-3 / 762-1 764-3 /
765-1 766-3 / 767-1 769-3

~~757-1 758-3~~ ~~759-1 761-3~~ ~~762-1 764-3~~ ~~765-1 766-3~~ ~~767-1 769-3~~

G3 = 912



G5 = pyrimidinyl (substd. by 1 or more G6)
 G6 = NO₂ / Me
 G17 = NH
 G52 = C(O)
 G55 = phenylene. (opt. substd. by (up to 2) 1043)

$\text{SO}_3^- \text{H}^+$
 1043


Patent location: claim 5

L29 ANSWER 23 OF 24 MARPAT COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 119:37437 MARPAT Full-text
 TITLE: Silver halide photographic material
 INVENTOR(S): Kato, Takashi; Hioki, Takanori; Ikeda, Tadashi
 PATENT ASSIGNEE(S): Fuji Photo Film Co., Ltd., Japan
 SOURCE: Eur. Pat. Appl., 103 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------------------------|------|----------|-----------------|----------|
| EP 532042 | A1 | 19930317 | EP 1992-115605 | 19920911 |
| EP 532042 | B1 | 19991222 | | |
| R: DE, GB, NL | | | | |
| JP 05072662 | A | 19930326 | JP 1991-261389 | 19910913 |
| US 5489505 | A | 19960206 | US 1995-397725 | 19950302 |
| PRIORITY APPLN. INFO.: | | | JP 1991-261389 | 19910913 |
| | | | US 1992-943674 | 19920911 |
| | | | US 1993-150793 | 19931112 |

AB The title photog. material contains a special bridge group-bearing cyanine dye I [Z1, Z2 = atoms necessary to form 5- or 6-membered N-containing ring; Q = atoms necessary to form 5- or 6-membered ring; R1 = alkyl, aryl, heterocycllyl; R2, R3 = alkyl; L1-L6 = methine group; m, n = 0, 1; M = ion necessary to

neutralize elec. charge; p = number necessary to neutralize elec. charge].
The photog. material has high sensitivity and excellent storage stability.

MSTR 2

G1 = 25-1 47-3



G6 = CH / 1 or more N

G8 = alkyl / 187

~~HN~~₇-G11

Patent location: claim 8

L29 ANSWER 24 OF 24 MARPAT COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 117:58797 MARPAT Full-text
TITLE: Silver halide emulsion
INVENTOR(S): Hioki, Takanori; Matsunaga, Atsushi
PATENT ASSIGNEE(S): Fuji Photo Film Co., Ltd., Japan
SOURCE: Eur. Pat. Appl., 146 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|-----------------------|------|----------|-----------------|----------|
| EP 474047 | A1 | 19920311 | EP 1991-114082 | 19910822 |
| EP 474047 | B1 | 19960612 | | |
| R: DE, FR, GB, IT, NL | | | | |
| JP 04104138 | A | 19920406 | JP 1990-221780 | 19900823 |
| JP 04104139 | A | 19920406 | JP 1990-221783 | 19900823 |
| JP 2767490 | B2 | 19980618 | | |
| US 5223389 | A | 19930629 | US 1991-748600 | 19910822 |
| EP 647878 | A2 | 19950412 | EP 1994-120560 | 19910822 |
| EP 647878 | A3 | 19970730 | | |

EP 647878 B1 20000112

R: DE, FR, GB, IT, NL

PRIORITY APPLN. INFO.:


JP 1990-221780 19900823

JP 1990-221783 19900823


EP 1991-114082 19910822

AB A photog. emulsion comprises ≥ 1 methine dye represented by the general formula (MET)_p[QrAr]_s [MET = an atomic group having a methine dye structure; Q = a divalent linking group; p = 1, 2; r = 1-4; q = 0, 1; Ar = an aromatic polycyclic group formed of ≥ 8 atoms containing ≥ 1 N atom, with the proviso that the N atom is in a form such that tautomerism does not produce -NH-. A photog. material is also claimed which contains a photog. emulsion layer comprising Ag halide grains containing Fe ions in an amount of 10^{-7} - 10^{-3} mol/mol Ag halide and having a localized phase with an Fe ion concentration ≥ 10 times that of the other portions. The photog. material exhibits a blue sensitivity difference of ≤ 0.1 between when it is developed after exposure in vacuum under 10^{-5} torr and when it is developed after exposure in air under 760 torr. The material shows reduced fluctuation of sensitivity during storage.

MSTR 2



G1 = 42-7 67-9 / 67-7 42-9



G2 = alkyl (opt. substd.) / NH2

G5 = 1 or more N / CH

Patent location: claim 3

Serial No.: 10/812,075

Search History

L1 1 SEA ABB=ON PLU=ON US2004-812075/APPS

FILE 'REGISTRY' ENTERED AT 09:48:18 ON 05 JUN 2007

L2 7 SEA ABB=ON PLU=ON (769192-99-6 OR 769193-00-2 OR 769193-01-3
OR 769193-02-4 OR 769193-03-5 OR 769193-04-6 OR 769193-05-7)/
RN

L3 1 SEA ABB=ON PLU=ON 769190-72-9/RN

FILE 'CAPLUS' ENTERED AT 09:50:30 ON 05 JUN 2007

L4 ANALYZE PLU=ON L1 1- RN : 1738 TERMS

FILE 'REGISTRY' ENTERED AT 09:53:14 ON 05 JUN 2007

L5 8 SEA ABB=ON PLU=ON (769190-72-9 OR 1655-07-8 OR 175278-12-3
OR 220996-80-5 OR 223131-01-9 OR 23631-02-9 OR 247570-24-7 OR
31058-81-8)/RN

L6 STRUCTURE UPLOADED

L7 2 SEA SSS SAM L6

L8 STRUCTURE UPLOADED

L9 2 SEA SSS SAM L8

FILE 'LREGISTRY' ENTERED AT 10:21:42 ON 05 JUN 2007

L10 0 SEA SSS FUL L8

FILE 'BEILSTEIN' ENTERED AT 10:22:14 ON 05 JUN 2007

L11 0 SEA SSS SAM L8

L12 0 SEA SSS FUL L8

FILE 'REGISTRY' ENTERED AT 10:23:30 ON 05 JUN 2007

L13 278 SEA SSS FUL L8

FILE 'CAPLUS' ENTERED AT 10:26:57 ON 05 JUN 2007

L14 3 SEA ABB=ON PLU=ON L13

L15 902 SEA ABB=ON PLU=ON SEKIGUCHI Y?/AU

L16 32 SEA ABB=ON PLU=ON KANUMA K?/AU

L17 21 SEA ABB=ON PLU=ON OMODERA K?/AU

L18 19 SEA ABB=ON PLU=ON BUSUJIMA T?/AU

L19 2458 SEA ABB=ON PLU=ON TRAN T?/AU

L20 9406 SEA ABB=ON PLU=ON HAN S?/AU

L21 54 SEA ABB=ON PLU=ON CASPER M?/AU

L22 757 SEA ABB=ON PLU=ON KRAMER B?/AU

L23 92 SEA ABB=ON PLU=ON SEMPLE G?/AU

L24 95 SEA ABB=ON PLU=ON ZOU N?/AU

L25 3 SEA ABB=ON PLU=ON (L15 OR L16 OR L17 OR L18 OR L19 OR L20 OR
L21 OR L22 OR L23 OR L24) AND L14

FILE 'MARPAT' ENTERED AT 10:36:37 ON 05 JUN 2007

L26 1 SEA SSS SAM L8

L27 24 SEA SSS FUL L8

FILE 'CAPLUS' ENTERED AT 10:39:22 ON 05 JUN 2007

L28 0 SEA ABB=ON PLU=ON L14 NOT L25

FILE 'MARPAT' ENTERED AT 10:40:40 ON 05 JUN 2007

L29 24 SEA ABB=ON PLU=ON L27 NOT L25

=>